==== Front J Hematol Oncol J Hematol Oncol Journal of Hematology & Oncology 1756-8722 BioMed Central London 998 10.1186/s13045-020-00998-9 Review Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy Yilmaz Ahmet 1 Cui Hanwei 1 Caligiuri Michael A. 2345 Yu Jianhua Jiayu@coh.org 2345 1 grid.261331.40000 0001 2285 7943The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210 USA 2 grid.410425.60000 0004 0421 8357Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E. Duarte Road, KCRB, Bldg. 158, 3rd Floor, Room 3017, Los Angeles, CA 91010 USA 3 grid.410425.60000 0004 0421 8357Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Los Angeles, CA 91010 USA 4 grid.410425.60000 0004 0421 8357Department of Immuno-Oncology, City of Hope Beckman Research Institute, Los Angeles, CA 91010 USA 5 grid.410425.60000 0004 0421 8357City of Hope Comprehensive Cancer Center and Beckman Research Institute, Los Angeles, CA 91010 USA 7 12 2020 7 12 2020 2020 13 16816 9 2020 12 11 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Natural killer (NK) cells are a critical component of the innate immune system. Chimeric antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding antigens, creating major opportunities in the fight against cancer. CAR NK cells have the potential for use as universal CAR cells without the need for human leukocyte antigen matching or prior exposure to tumor-associated antigens. Exciting data from recent clinical trials have renewed interest in the field of cancer immunotherapy due to the potential of CAR NK cells in the production of “off-the-shelf” anti-cancer immunotherapeutic products. Here, we provide an up-to-date comprehensive overview of the recent advancements in key areas of CAR NK cell research and identify under-investigated research areas. We summarize improvements in CAR design and structure, advantages and disadvantages of using CAR NK cells as an alternative to CAR T cell therapy, and list sources to obtain NK cells. In addition, we provide a list of tumor-associated antigens targeted by CAR NK cells and detail challenges in expanding and transducing NK cells for CAR production. We additionally discuss barriers to effective treatment and suggest solutions to improve CAR NK cell function, proliferation, persistence, therapeutic effectiveness, and safety in solid and liquid tumors. Keywords Chimeric antigen receptorNatural killer cellsT cellsCancer immunotherapyhttp://dx.doi.org/10.13039/100000002National Institutes of HealthAI129582CA247550NS106170CA223400CA210087CA068458CA163205Caligiuri Michael A. Yu Jianhua issue-copyright-statement© The Author(s) 2020 ==== Body Background Natural killer (NK) cells are large granular lymphocytes with surface markers CD3−CD56+NKp46+ in humans. They have been recognized as a subset of innate lymphoid cells (ILCs) that lack antigen receptors with recombination activating gene (RAG)-dependent rearrangement [1, 2]. There are three groups of ILCs (Groups 1–3), each with distinct functions and expression profiles of key transcription factors. NK cells are included in Group 1 ILCs, which also include innate lymphoid cell 1 (ILC1). Both NK cells and ILC1 depend on the transcription factor T-bet for their proper function and development, and secrete interferon-γ (IFN-γ) rather than type 2 cytokines (IL-5 and IL-13), IL-17, or IL-22 [3]. The development of NK cells involves bone marrow and extra-medullary sites such as tonsils, uterus, and liver [4–6]. The NK cell developmental process is initiated in the bone marrow microenvironment where hematopoietic stem cells differentiate into common lymphoid progenitors (CLPs) which can give rise to all subtypes of lymphoid cells. CLPs first develop into NK progenitor cells, and then differentiate into immature and finally mature or resident NK cells. These developmental processes may occur in different organs or tissues [7–9]. NK cells are able to recognize and kill “stressed cells” including cells infected with viruses, allogeneic cells, and tumor cells without prior sensitization in a non-HLA (human leukocyte antigen)-restricted manner. The effector functions in NK cells are regulated through a balance of signals delivered by activating and inhibitory receptors as well as cytokines such as IL-2, IL-12, IL-15, or IL-18 [10]. The inhibitory receptors, including inhibitory killer immunoglobulin receptors (KIRs) and NKG2A/CD94 in humans, keep NK cells in a quiescent state through the recognition of constitutively expressed self-MHC class I molecules on healthy cells. A variety of activating receptors are expressed on NK cells, exemplified by NKG2D, CD16, natural cytotoxicity receptors (NCRs), and activating KIRs. The activating receptors contribute to NK cell activation via recognition of host-derived or pathogen-encoded ligands or antibodies [11, 12]. NK cells play critical roles against tumor initiation and metastasis [13, 14]. Their activation by tumor cells, which depends on the type of ligands on the surface of the tumor cells, can be accomplished via several mechanisms. The MHC-I molecules on target cells, which inhibit NK cell function through binding to inhibitory receptors on NK cells, are often reduced or lost in tumors (missing-self recognition). Activation of NK cells can also be triggered by upregulation of ligands on tumor cells by certain therapeutic agents [15–17]. Activated NK cells are capable of eliminating tumor cells through direct cell cytotoxicity and/or production of pro-inflammatory cytokines. They can directly release perforin and granzymes to kill tumor cells. They can also mediate antibody-dependent cellular cytotoxicity (ADCC) via the membrane receptor CD16, or apoptotic pathways mediated by Fas ligand (FasL) or TNF-related apoptosis-inducing ligand (TRAIL) [18]. In addition, cytokines and chemokines such as IFN-γ and granulocyte macrophage colony stimulating factor (GM-CSF) produced by NK cells can modulate immune responses of other cells. For example, IFN-γ helps in activation of CD8 + T cells, monocytes, and macrophages [4, 19, 20]. Although NK cells are able to recognize and lyse tumor cells, the tumor cells develop their own mechanisms to evade recognition by NK cells or repress NK cell function. For example, tumor cells can produce immunosuppressive cytokines such as IL-10 or transforming growth factor-beta (TGF-β) to repress NK cell function [21, 22]. They may also reduce expression of tumor-associated antigens (TAAs) or elevate expression of MHC class I-related molecules to inactivate NK cells [23]. Engineering NK cells to express a chimeric antigen receptor (CAR) may overcome immune evasion. Although several approaches including CAR T cells, checkpoint inhibitors, antibodies, antibody–drug conjugates, and tumor vaccinations are being investigated [24, 25], development of “off-the-shelf” CAR-modified NK cells is an especially promising and unique approach in developing sustainable anti-cancer immunotherapeutic products. Chimeric antigen receptors (CARs): structure and function A CAR is a functional hybrid antigen receptor usually combining variable regions of an antibody with the constant region of a T cell receptor (TCR), grafting an immune cell with the specificity for TAA expressed on tumor cells [26]. A typical CAR is composed of a signal peptide, single-chain antibody variable fragment (scFv), and transmembrane and intracellular signaling domains. A linker combines the variable regions of heavy and light chains of an antibody molecule. A hinge, also called spacer, connects the scFv to the transmembrane domain. scFv is derived from a tumor-specific antibody and can target any antigen expressed on tumor cell surface [27]. In some CARs, a ligand of a tumor antigen is used [28, 29]. An intracellular signaling domain is derived from immunoreceptor tyrosine-based activation motifs (ITAMs) of TCR or a cytoplasmic domain of other activating receptors. Phosphorylation of ITAMs recruits adapter molecules, stimulates downstream pathways, and activates immune cells [30, 73]. The first-generation CARs contained only the CD3ζ chain, the common signal transducing subunit of TCR, or FcRγ subunits as the intracellular signaling domain [31–33]. They were not effective in initiating T cell activation or tumor elimination as they lacked co-stimulatory signaling required for full T cell activation. To improve the immune cell response to tumor cells, second-generation CARs were created by adding one of the T cell co-stimulatory molecules such as CD28, 4-1BB (CD137), ICOS, or OX40 (CD134) in addition to CD3ζ. The third-generation CARs include three signaling domains (for example, CD3ζ and two co-stimulatory domains) [34, 35]. There is no consistent evidence suggesting increased performance in the third—compared to the second—generation CARs. The type of co-stimulatory domain used can dramatically influence effector functions mediated by the CAR. For example, 4-1BB co-activation results in development of T memory cell characteristics, whereas CD28 co-activation results in enhanced T cell activation and expansion [36]. Generation of vectors for CARs CARs can be generated against any of the surface antigens expressed on tumor cells. However, the target should have a specific antigen density to avoid "on-target, off-tumor" effects. Studies in T cells have shown that target density between 200 and 2000 copies per cell is optimal to avoid damage to the normal cells [37]. Generation of a CAR usually starts with an scFv derived from an antibody, composed of heavy and light chains [38]. Recently, nanobodies composed only of heavy chains are being utilized for CAR NK cell production [39]. These single-chain antibodies not only possess specificity comparable to scFvs but also are much smaller in size, facilitating transduction. However, their use in CAR NK cell production is currently at the experimental stage. Usually, a signal peptide is introduced in the front of an scFv. A linker that connects heavy and light chains usually contains the (G4S)3 or (G4S)5 signature that provides flexibility for accurate folding of connected protein domains [40, 41]. A spacer, also referred to as a hinge, usually derived from IgG, CD8α, or CD28, plays a critical role in specificity of the CAR-bearing immune cells [41]. Adjusting the length of spacer may help optimize the distance between CAR-bearing cells and target cells for an optimal immunologic synapse (IS) formation and specificity. Use of CAR T cells created using spacers with suboptimal length results in off-target effects. The downstream CAR component(s) are co-stimulatory domain(s) that can be shared between CAR NK and CAR T cells [42, 43], followed by CD3ζ. With the rapid development of DNA synthesis technology, many CAR sequences are now synthesized by a vendor if the DNA sequences encoding the scFv are known. All CAR components or a cassette are commonly cloned into a retrovirus- or lentivirus-based expression vector, which is then used to transduce primary NK cells or NK cell lines [44] (Fig. 1). In some instances, an inducible iCaspase can be incorporated as a safety switch for use in case of adverse reactions [10]. Different CAR designs and detailed engineering approaches have been reviewed elsewhere [45].Fig. 1 Representative steps in CAR NK cell manufacturing for immunotherapy, RCL/RCR replication competent lentivirus/retrovirus measured by qPCR for detection of DNA encoding a viral envelope CAR T cells vs. CAR NK cells for cancer immunotherapy CAR T cells targeting CD19 or other B cell markers such as CD20 have achieved remarkable responses in patients with B cell malignancies including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and lymphoma [26, 46–48]. CTL019 (Kymriah, tisagenlecleucel) marketed by Novartis achieved 82.5% overall remission rate (ORR), which includes 40 complete remission (CR) and 12 CR with incomplete hematologic recovery (CRi) in 63 patients with ALL. A biologic license application for Kymriah was assessed based on B2202, a single-arm, open label, multi-center phase 2 study including 107 patients who signed consent. There were 19 patients who were not eligible due to death before the study began, unacceptable apheresis, incomplete screening before the cutoff date, or loss of eligibility for other reasons [49]. Additional twenty patients from the remaining 88 were further excluded due to adverse events, manufacturing failure, death, or pending infusion. The remaining 68 patients were included in the safety set, but five were further excluded from the efficacy set because the products were manufactured in Germany, and thus, 63 patients were included in the ORR calculation above. The ORR of 82.5% was an impressive outcome compared to less than 20% of the standard treatment, and thus, the product received an expedited approval by the US Food and Drug Administration (FDA) [36, 49, 50]. The intent-to-treatment (ITT) rate, as defined by the number of patients with ORR divided by the number of patients consented, was 48.5% (52/107). In the Yescarta study, 111 patients were enrolled, but 10 withdrew [51]. Objective response rate was 72% (51% for advanced cases). In the treatment of DLBCL, CR rates were higher in the Yescarta study compared to the Kymriah study (72% vs. 50%). It is unknown whether this difference was influenced by differences in the number of cells infused (60–600 million cells were infused if the body weight was greater than 50 kg in the Kymriah study and 2 million cells per kg were infused in the Yescarta study). CD19-CAR T cells are the first CAR T cell-based drug approved by the FDA. Studies to develop CAR T cells for treating other tumor types including solid tumors are increasing [52–55]. However, there have been reports of serious side effects in the clinic associated with CAR T cell therapy including cytokine release syndrome (CRS), “on-target, off-tumor” toxicity, neurologic symptoms, graft vs. host disease (GvHD) if used in an allogeneic setting, and tumor lysis syndrome. For example, 94% of the patients in the Yescarta study and 74% in the Kymriah study had CRS and at least four two patients in each study died from CRS [51]. CRS is a rapid and massive release of inflammatory cytokines such as IFN-γ, TNF-α, and IL-6 into circulation [47]. It can present with symptoms such as high fever, malaise, fatigue, myalgia, nausea, anorexia, tachycardia/hypotension, capillary leak, or disseminated intravascular coagulation (reviewed by Bonifant et al. (2016) [56, 57]. Other studies have also shown that CRS by CAR T cells can be life-threatening [56–58]. In addition, CAR T cells may attack not only tumor but also normal cells, resulting in on-target, off-tumor toxicity. For example, HER2-specific CAR T treatment resulted in acute respiratory failure and death in a patient with metastatic colon cancer possibly due to low levels of HER2/neu expressed in the pulmonary parenchyma or vasculature [59]. Severe neurological toxicities such as acute cerebral edema resulting in brain death a few hours after initial appearance of neurological symptoms have also been reported in treatment with CD19-CAR T cells [60]. In the separate Kymriah and Yescarta studies, although, respectively, noted in 72% and 87% of the patients treated with CAR T cells, no deaths were attributed to neurotoxicity. CAR T cells obtained from allogeneic sources may also result in GvHD [61]. Disabling the endogenous TCR has the potential to avoid or lower GvHD risk. Endogenous TCR has been disabled using recent techniques such as CRISPR/Cas9, TALEN, zinc finger endonucleases, and receptor blockage using an array of proteins [61]. Some of these techniques are currently being evaluated for clinical use. Compared to T cells, NK cells offer many advantages for cancer immunotherapy (Table 1). For example, it has been reported that allogeneic NK cells do not need complete HLA matching and cause little or no GvHD compared to allogeneic T cells [61–63]. In fact, there is experimental data in animals showing that NK cells not only do not cause GvHD but also prevent it in some cases by inhibiting activated alloreactive T cells while retaining graft vs. tumor effects [63]. On the contrary, CAR T cells can cause GvHD even when HLA-matched as minor mismatches may still be provocative [64]. Additionally, the cytokine levels produced by NK cell infusions are moderate [65] compared to the levels seen in life-threatening cases of CRS observed in CAR T cell trials [61].Table 1 Comparison of clinical efficacy and future prospects in CAR T cell versus CAR NK cell cancer immunotherapya,b Parameter CAR T Primary CAR NK CAR NK-92 Source PB PB or UCB Cell line Need for in vitro expansion before infusion Yes Yes No Pre-activation and differentiation Needs CD3/CD28 stimulation Requires feeder cells and/or IL-2 or other cytokines for optimal growth Requires IL-2 for optimal growth Viral transduction efficiency Variable Variable High transduction efficiency Side effects  Neurotoxicity Yes (reported in 58–87% of the patients in the Kymriah and Yescarta clinical trials) No No  CRS Yes (reported in 74–94% of the patients in the Kymriah and Yescarta clinical trials) No No  Long-term side effects Yes, CAR T cells can persist in circulation for years Limited in vivo survival without IL-15 and persistent growth for over a year with incorporated IL-15 Short persistence, the cell line needs to be irradiated prior to infusion Killing activity Kills only tumor cells carrying TAA in an MHC-independent manner; produces slow response Kills tumor cells regardless of their MHC status with some preference in killing tumor cells lacking MHC-I; quick response without prior activation Similar to primary CAR NK ADCC activity No Yes, due to CD16 expression Similar to primary CAR NK when NK-92 CAR NK cells are transduced with CD16 Prospects for clinical use Impressive clinical outcomes have already been reported; CAR T treatment has been approved by the FDA (Kymriah for ALL and Kymriah and Yescarta for DLBCL [51] Being developed and promising Being developed and combined with other agents "Serial" killing ability Yes Yes, one NK cell can kill up to 5 tumor cells [220] Unknown because cells  are irradiated before infusion Production efficiency Low; needs to be prepared individually for each patient and requires coordination between production facility and clinica High due to donor availability and the off-the-shelf potential High; unlimited expansion potential of the cell line Cost of treatment Expensive; approximately $373,000 USD [221] Relatively less expensive due to off-the-shelf potential Relatively less expensive than CAR T and primary CAR NK cells due to unlimited expansion potential Potential for production of "off-the-shelf" anti-cancer products Low to moderate; TCR knock-out studies are ongoing, but disabling TCR may lower T cell activity and/or survival and may be technically challenging High; UCB NK cells may have better survival rates than PB NK cells after thawing or infusion Very high; unlimited expansion potential a10% of the patients died or were dropped and 80% needed bridge chemotherapy while waiting for the CAR T cell product during Kymriah and Yescarta clinical trials, complicating interpretation of the results [51]. This table has been partially adopted from Kurlander (2017), O’Leary (2017) [49, 51], and Klingemann (2014) [65] bDLBCL diffuse large B-cell lymphoma, PB peripheral blood, UCB umbilical cord blood NK cells have a limited life span in circulation and do not produce memory cells except for some viruses. Therefore, a primary-NK cell-based CAR approach may not need to be modified to include a suicide gene as a safety switch [66]. A further potential advantage of using CAR NK cells is that, unlike CAR T cells, they can be derived from umbilical cord blood (UCB) or cell lines such as NK-92, both of which have the potential for use as an “off-the-shelf” therapeutic product [61]. The safety of CAR NK-92 cells was tested in acute myeloid leukemia (AML) patients in a recent “first-in-man” clinical trial targeting CD33 [67]. Although the CAR NK-92 cells did not seem significantly beneficial in that particular study, injection of approximately five billion irradiated cells per patient did not produce any significant adverse side effects, suggesting that injection with a large number of NK-92 cells may be safe. A recent clinical trial (NCT03056339) produced exciting evidence supporting the potential for production of “off-the-shelf” NK cells with significant benefits in relapsed or refractory CD19-positive lymphoma and leukemia [68]. HLA-mismatched NK cells isolated from UCB and transfected with a retrovirus-based vector expressing anti-CD19 CAR, iCaspase-9, and IL-15 were administered in 11 patients with CLL or non-Hodgkin’s lymphoma. Nine patients received haplo-mismatched CAR NK cells and 2 patients received completely mismatched CAR NK cells.  Seven patients had a complete response and one had a partial response with remission of the Richter’s transformation component. These patients had relapsed/refractory tumors and were heavily pre-treated using conventional methods before starting CAR NK cell therapy. The patients had a median of four lines of therapies before beginning the CAR NK cell treatment. Five were CLL patients who failed to respond to ibrutinib and other therapies. Six were lymphoma patients, four of whom failed to respond to autologous hematopoietic stem cell transplantation (HSCT), and two had refractory disease. All but one patient had at least two prior relapses. An objective response of eight patients (73%) was observed during a follow-up period of 13.8 months. In all eight patients, a response was seen in the first month of the CAR NK treatment. An additional patient had a complete response, but his response was not attributed to CAR NK cell therapy. It was possible to bridge five of the eight patients who responded CAR NK therapy to HSCT, rituximab, venetoclax or lenalidomide treatment after CAR NK-cell-induced remission. None of the side effects seen with CAR T cells were noted. Excluding transient myelotoxicity, there was no neurotoxicity, elevation in IL-6 levels, CRS, or GvHD. The infused CAR NK cells expanded and persisted in vivo for at least 12 months [68]. Sources to obtain NK cells for immunotherapy NK cell lines as well as primary NK cells from peripheral blood (PB), UCB, or induced pluripotent stem cells (iPSCs) have been used for CAR NK cell production. Several NK cell lines such as NK-92, NKG, YT, NK-YS, HANK-1, YTS, and NKL are commercially available [69]. NK-92 is the most widely used cell line and has already entered into clinical trials [70]. In comparison to PB NK cells, NK-92 cells are easier to expand and transduce and do not carry any contaminating T cells that may cause GvHD [71]. In addition, their production is inexpensive and easy to standardize, and they do not express fewer inhibitory KIRs that restrict NK effector functions [72, 73]. However, there are also several disadvantages associated with the use of NK-92 cells. For example, the cells must be irradiated before infusion into patients to prevent unrestricted cell growth, thereby limiting their capacity for in vivo expansion. Additionally, the NK-92 cell line carries Epstein–Barr virus and has an abnormal genome. NK cells constitute only about 10% of the PB lymphocytes and thus need expansion in vitro to obtain a sufficient quantity for a therapeutic effect. Various methods to enhance expansion of NK cells isolated from PB have been detailed below in the "Challenges in expanding CAR NK cells" section. NK cells from PB, and consequently CAR NK cells produced from PB, are potent killers of tumor cells as they are fully matured [74, 75]. Another well-studied source of primary NK cells is UCB, which may offer several advantages. Approximately 15 to 30% of UCB lymphocytes are NK cells, which can result in more than NK cells found in PB [76, 77]. There are less contaminating T cells in UCB compared to PB, which reduces the risk of GvHD [78–80]. In addition, NK cells in UCB may be less likely to undergo rejection by the patient compared to PB NK cells. However, NK cells isolated from UCB are immunologically immature and initiate only a weak immune response against target cells after being activated by stimuli such as cytokines or alloantigens [81]. Therefore, CAR NK cells derived from UCB may be less cytotoxic than those derived from PB [82]. UCB is easy to collect with no harm to the mother or child and almost never contaminated with Epstein–Barr virus or cytomegalovirus. A recent study showed that CD19-CAR NK cells isolated from UCB transduced to express IL-15 and an iCaspase-9-based suicide gene had effective and persistent anti-tumor activity in NOD scid gamma (NSG) mice [83]. The incorporated IL-15 dramatically increased anti-tumor activity in the CD19-CAR NK cells. This study has been translated into a clinical trial with impressive outcomes [68]. Other less common sources for obtaining NK cells include pluripotent stem cells (human embryonic stem cells or iPSCs or adult stem cells (CD34+ hematopoietic stem cells) [84–88]. Recently, Li et al. (2018) utilized NK cells derived from human iPSC with a mesothelin-CAR modification as a potential source for "off-the-shelf" CAR NK cells for anti-cancer immunotherapy [89]. Targets for CAR NK cells The choice of targets for CARs depends on the type of tumor studied. Several proteins expressed by tumor cells are being targeted in preclinical or clinical studies. In lymphoid malignancies, the most widely targeted cell surface proteins include CD19 and CD20 [90–97]. CAR NK cells for multiple myeloma (MM) have targeted CD138 and CS1 [44, 98]. CS1 is a cell surface glycoprotein highly and ubiquitously expressed on the surface of myeloma cells [99]. In our previous studies, we found that CS1-CAR NK cells were able to target MM cells and eradicate MM both in vitro and in vivo [44]. MM cancer stem cell-like cells (CSCs) expressed significantly higher levels of CS1 than any other cell type, making them especially vulnerable to being eradicated by CS1-CAR NK cells [100]. Thus, CS1-CAR NK cells may prevent MM relapse via targeting and eliminating MM CSCs. CD22, important in B cell trafficking, can be targeted for treatment of B-cell lymphoma [101]. CD7, important in lymphoid development and B/T cell cross talk, can be targeted in ALL, whereas CD33, a lectin inhibiting multiple cellular functions, can be targeted in AML [102]. As for solid tumors, a set of targets have been evaluated. A well-known target is HER2 that is up-regulated in several cancers including breast, colon, and ovarian cancers [103]. HER2-CAR cells using PB NK cells or NK-92 cells have been used to treat breast and ovarian cancers and neuroblastoma [104–108]. GD2 has been targeted for treating neuroblastoma using CAR NK-92 cells [109, 110]. GD2-CAR NK-92 cells effectively lyse multi-drug resistant neuroblastoma cell lines and show significant anti-tumor activity in xenograft mouse models [110]. Additional antigens being explored as CAR NK cell targets in solid tumors include EGFR, GPA7, CD244, and EpCAM [44, 111–114]. EGFR is one of the most frequently amplified genes in glioblastoma, the most frequent and lethal type of brain tumor [115]. Approximately 20–40% of the EGFR-amplified tumors harbor the EGFR variant III (EGFRvIII). In our previous work, we found that EGFR-CAR NK cells targeted glioblastoma with both wild-type EGFR and EGFRvIII. EGFR-CAR NK cells were strongly cytotoxic, inhibited glioblastoma growth, and prolonged survival in tumor-bearing mice [112]. Use of CAR NK cells in combination with oncolytic viruses has been tested to eliminate solid tumors. Combination of EGFR-CAR NK-92 cells with herpes simplex virus 1-based oncolytic virus (oHSV-1) results in increased efficiency in killing a breast cancer cell line engrafted into the brain [116]. Additional targets being evaluated in recent clinical trials include a prostate-specific membrane antigen (PSMA) expressed over 100 times higher in prostate tumor tissues than normal prostate and the tumor differentiation antigen mesothelin in ovarian cancer [117, 118]. CAR NK cells and CAR NKT cells have been reported to target MUC1, a glycoprotein that creates a significant barrier preventing drugs from binding to their targets on cancer cells [119]. ROBO1, important in neuronal development, is being evaluated for treatment of pancreatic cancer [120]. Challenges in CAR NK production Challenges in transducing CAR NK cells Several methods including electroporation and viral transduction methods have not achieved full transduction efficiency in CAR NK cell production (Table 2). Major groups of viruses tested for transduction include retro-, lenti-, vaccinia-, and adenoviruses. Vaccinia- and adenoviruses are not well suited for NK cell transduction as they may change the phenotype of the cells or may not bind receptors on NK cells [121]. In addition, transduction with adenoviruses is transient as they rarely integrate into the host genome [122]. Although transduction with retro- and lentiviral vectors has the advantage of achieving stable transgene expression, they may induce oncogenic transformation due to their potential for insertional mutagenesis [66]. For example, leukemia due to insertional mutagenesis has been reported in patients undergoing gene therapy with CD34+ cells transduced with retroviruses to restore IL-2 receptor expression [123]. Several studies have reported that insertion of retroviruses is more common in transcriptionally active than silent genes and transcription factor binding sites and thus may not be a completely random event. Likewise, lentiviruses also show strong preference for integrating into the transcriptionally active genes [124, 125]. Retroviruses can only infect dividing cells. NK cells also have a short half-life in vivo, yet expressing membrane bound IL-15 increases viability and cytotoxicity in NK cells transduced with retroviruses [126]. Vectors based on lentiviruses, a subclass of retroviruses, are more popular likely because they are relatively safer [61].Table 2 Studies aimed at improving transduction efficiency in NK cells Vector Cells used for transduction Transduction efficiency Main findings References Lentivirus Primary NK cells 29% (range 16–41%) with excellent viability Multiplicity of infection (MOI) of 25 is optimal. Higher MOI results in higher transduction but lower viability. Transgene expression peaked at 5 days post-transduction and was detectable for 2 weeks [222] Lentivirus Primary NK cells and the YTS NK cell line 98% in the YTS NK cell line, up to 80% in primary NK cells Transduction efficiency was 20% when fresh primary NK cells were transduced without cytokines. The efficiency increased up to 20–50% when IL-2 plus IL-12 were added and 80% when PHA, a lectin, was added to the culture. The transduction efficiency remained stable in the presence of PHA for 10 days in culture [223] Lentivirus Primary NK cells Depending on cell type, BX795 addition increased transduction efficiency up to tenfold Inhibition of TBK1/IKKε complex by BX795 significantly improved transduction efficiency. Lentivirus RNA is probably recognized by pathways involving TBK1/IKKε complex involved in anti-viral response pathways, which may also include RIG-I, MDA-5, and TLR3 [224] Lentivirus Primary NK cells (mice) 40% IL-2 is not required for transduction [225] mRNA transfection and lentivirus Primary NK cells, NK-92, and NK cells from UCB In NK-92 (56% with mRNA, 26% with lentivirus), in primary NK (approximately 10% with mRNA), and in UCB (12% to 73% with lentivirus) mRNA delivery was more effective than lentiviral transduction in transducing the NK-92 cell line (56% vs. 26%) [226] Lentivirus NK-92, LNK, YT, and DERL7 cell lines 15% in NK-92 and 30–40% in LNK, YT, and DERL7 cell lines Lentiviruses are more efficient than retroviruses that require multiple rounds of transduction [121] Retrovirus Primary NK cells 27–47% on days 5–6 of the culture and 52–75% 21 days after initial culture  MOI of 10 yields highest transfection efficiency [227] Retrovirus UCB NK cells 49% NK cells expressing IL-15 were detectable up to a year after infusion [68] Retrovirus UCB NK cells 66.6% NK cells purified from UCB and transduced with iCaspase-9, IL-15, and a CD19-specific CAR showed significant toxicity toward CD19 + tumors [83] Alternative methods developed to avoid risks associated with the viral delivery of genes have not been fully successful. A transposon-based gene delivery system has been reported, but its design still needs improvement [61]. mRNA delivery of CARs into NK cells has relatively high success rates, but the transfection is only transient. CD19-CAR NK generated by trogocytosis avoids side effects of viral transduction. However, this approach also has remained at the experimental stage [127]. Using nucleofection or electroporation for gene delivery results in 1–90% transient transfection efficiency with viability ranging from 45 to 97%, suggesting that the technology is not stable or very reliable. Several approaches and compounds including dextran, PHA, and BX795 have been tested to improve transduction efficiency in NK cells (Table 2). Dextran, a cationic polymer, significantly increases transduction efficiency in human and mice primary NK cells transduced with lentiviruses [128]. Magnetofection improves lentivirus-mediated gene delivery [129]. A modified 3D nanochannel-electroporation (NEP) method that can transfect 100–200 cells at a single-cell resolution has been developed [130]. The method involves precisely positioning cells on nanochannels allowing precise transfection. The method has shown nearly 70% transfection efficiency using CAR NK cells. However, this technology also delivers CARs only transiently. Challenges in expanding CAR NK cells A second significant challenge in CAR NK research is the limited expansion of NK cells in vitro and especially in vivo. Expanding CAR NK cells, especially PB NK cells, to clinical scale in vitro is difficult because a large number of NK cells are needed for immunotherapy and NK cells comprise only about 10% of the PB lymphocytes and therefore need to be expanded in culture [131]. Several methods have been developed to improve in vitro expansion rates in purified PB NK cells [90, 132–135]. A common method involves co-culturing PB NK cells with K562 feeder cells genetically modified to express IL-15 and the adhesion molecule 4-1BBL [90]. Telomere shortening seen in NK cells expanded by this technology can be prevented by expressing membrane bound IL-21 [135]. An approximate 2000-fold expansion of the NK cells from fresh or cryopreserved UCB in two weeks was achieved using these artificial antigen-presenting cells [136]. Expanded cells retain high expression levels of NKp44, NKG2D, TRAIL, and FasL, and their killing activity does not decrease compared to the fresh NK cells [137]. Nevertheless, NK cell exhaustion and loss of expansion capacity remain as concerns in long-term culturing exceeding 4 weeks. Limited in vivo expansion of NK cells after infusion due to unknown reasons is an especially significant challenge. Studies using iPSCs show that in vivo expansion rates in CAR NK and CAR T cells are correlated with their anti-tumor activity [89]. IL-2 diphtheria toxin fusion protein (IL-2DT) infusion may help in vivo expansion of haploidentical NK cells in AML patients by inhibiting Tregs [138]. A recent phase 1/2 clinical trial has shown that incorporating IL-15 into anti-CD19 CAR NK cells results in significant improvement in in vivo expansion [68]. A UCB unit was thawed and cultured in the presence of K562 expressing IL-21 and 4-1BBL and IL-2. Cells were transduced with an anti-CD19 CAR NK vector expressing IL-15 and iCaspase-9 on day 6, expanded, and harvested for infusion on day 15. As noted above, eight out of the eleven (73%) patients had responses up to 13.8 months. Expansion, as measured by real-time PCR (RT-PCR) (copies of the viral genome per micrograms of genomic DNA), was detected three days after infusion and persisted for over a year. Expansion was seen only in patients that responded to the treatment. Challenges in CAR NK cell therapy in solid tumors The exciting results from Liu et al. observed in CAR NK cell therapy in liquid tumors [68] have not yet been seen in solid tumors possibly due to challenges such as solid tumor heterogeneity and the hostile tumor microenvironment (TME). CD19 in leukemia and lymphoma is highly and homogenously expressed on the surface of malignant B cells, and the CD19-CAR NK cells do not face substantial anatomical barriers in the blood compartment before establishing a contact with their targets. In solid tumors, however, the CAR NK cells must travel in bloodstream, migrate into the tissue, and establish a contact with the tumor cells while battling many inhibitory factors in the TME (Table 3).Table 3 Challenges in building more efficient CAR NK cells for treatment of solid tumors and possible solutionsa Challenges Possible solutions References Lack of available targets  TAA expression not homogenous Use of oncolytic viruses in combination therapy or bi-specific CARs [116, 228]   Clonal evolution   On-target, off-tumor effects Anatomical barriers   Insufficient trafficking or infiltration Intra-tumoral injection of CAR NK cells; focused ultrasound guided delivery of CAR NK cells into tumor; targeting tumor vasculature; CAR NK cells expressing a chemokine(s) [149, 155] Locoregional injection, use of stronger co-stimulatory domains, lymph depletion, in vivo administration of chemokine or cytokine-expressing CARs [146, 169] Insufficient NK cell proliferation and/or activation in vivo   Immunosuppressive TME TGF-β inhibition through neutralizing antibodies or dominant negative receptors [229] Use of cytokines such as IL-2, IL-15, IL-12, or IL-18 to simulate NK cell proliferation and activation [68] Inhibition of checkpoint blockades using anti-PD1, anti-TIGIT, etc [165]   Metabolic abnormalities Metabolic stimulation through inhibition of CD73 or arginase [162]   NKG2D inhibition by TME NKG2D activation through histone deacetylase inhibitors [160, 230] aTAA tumor associated antigens, TME tumor microenvironment CAR NK cell therapy seems more promising in breast, ovarian, and prostate cancers than other types of solid tumors because these tissues are easily and safely accessible and destruction of the normal tissue can be tolerated. In addition, specific antigen targets such as PSMA or prostate stem cell antigen (PSCA) are already available for targeting prostate cancer [139]. Indeed, transduction of YTS cell lines with DAP12-based anti-PSCA CAR induces strong phosphorylation of ZAP70 and fully eradicates tumors in a portion of the mice tested [140]. CAR NK-92 cells expressing EpCAM accumulate in prostate tumor and are highly cytotoxic against EpCAM+ prostate cancer cells even at low doses [141]. iPSCs-derived CAR-NK cells targeting mesothelin have shown to have similar efficacy similar to that of CAR-T cells but with fewer toxicities [89]. In breast cancer, NK-92 cells expressing a HER2-specific CAR enhance killing of human breast cancer cell lines and increase survival in mice breast and renal cell carcinoma (RCC) models [107]. CAR NK cells targeting EGFR derived from PB are effective in triple-negative breast cancer (TNBC) both in vitro and in vivo [142]. A recent study focused on tissue factor (TF) highly expressed in 50–85% of the TNBC patient tumors with a FVII as a ligand [143]. FVII-CAR NK-92MI cells expressing CD16 are effective in vivo and enhance tumor killing by TF-targeting antibody-like immunoconjugates (L-ICON), in which FVII was fiused to the Fc fraction of IgG1. Major challenges in the use of CAR NK cells for treatment of solid tumors can be categorized into the following groups: Lack of available targets and antigen heterogeneity The first step in designing CARs is to locate a target antigen highly and uniformly expressed on the tumor cell surface. In solid tumors, most TAAs are expressed by cells not only in tumor but also in vital organs, making it impossible to avoid “on-target, off-tumor” effects [144]. In addition, TAA expression may be dramatically different between single cell clones from the same tumor due to clonal evolution and downregulation of TAA expression by tumors to evade immune surveillance. Bispecific CARs, composed of two scFvs recognizing two different antigens on the same CAR and activated only when both antigens are engaged, have been successful in improving specificity in prostate cancer [145]. Anatomical barriers Local injection, intra-peritoneal injection, and focused ultrasound-guided delivery of CARs into tissues have been experimented to overcome the anatomical barriers faced by the immune cells carrying CARs in solid tumors. In orthotopic models mimicking human pleural malignancies, pleural injection of CAR T cells is more effective and results in longer functional persistence than the i.v. injection [146]. Intrapleurally administered CAR T cells were able to circulate and persist in the periphery, suggesting that locally accessible sites may serve as “distribution centers” for CAR T therapy. Regional administration of CAR T cells was additionally useful in reducing the therapeutic dose of the CAR T cells. Endothelial cells in tumor vasculature have been targeted and successfully lysed by anti-PSMA-CAR T cells [147], as PSMA is expressed in neovasculature [148]. Anti-HER2 CAR NK-92 cells were delivered into the brain of mice with metastatic breast cancer using focused ultrasound [149]. The authors applied ultrasound bursts through intact skull combined with i.v. injection of microbubbles that temporarily allowed passage of NK-92 cells from the blood brain barrier into the brain without significant tissue damage. Limited CAR NK cell trafficking and infiltration into tumor sites The number of NK cells infiltrating into tumor has a prognostic value in solid tumors including gastric, lung, and colorectal cancers [150]. CARs that express chemokine receptors (CCRs) matching CC chemokine ligands (CCLs) expressed by the tumor cells acquire increased infiltration capabilities. Wennerberg et al. (2015) reported that in vitro expansion of NK cells was associated with a tenfold increase in CXCR3 expression compared to resting NK cells. Expanded cells migrated strongly toward CXCL10-transfected melanoma, but not CXCL10-negative tumor cells [151]. NK cells expressing CXCR2 show increased migration toward tumors expressing CXCR2 ligands [152]. The cells additionally show increased calcium mobilization, cytotoxicity, and adhesion properties. Overexpression of CXCR4 in anti-EGFRvIII CAR NK cells results in increased chemotaxis toward CXCL12/SDF-1α-secreting glioblastoma cells, complete tumor remission in a number of mice, and increased overall survival [153]. Oncolytic viruses are anti-tumorigenic and may also be anti-angiogenic through negative regulation of VEGF expression [154, 155]. In addition, oncolytic viruses induce an inflammatory immune response and enhance immune cell trafficking by modifying the TME [155]. Our group first explored the concept of combining anti-EGFR CAR NK cells and oncolytic virus therapy in a metastatic breast cancer animal model. The combination of EGFR-CAR NK-92 cells with oHSV-1 resulted in more efficient killing of breast cancer tumor cells engrafted into the brain compared to monotherapies and significantly improved survival of mice bearing breast cancer tumor cells in the brain [116]. Immunosuppression in the TME due to TGF-β Tumors express immunosuppressive factors including TGF-β, IL-10, PD-1, or arginase. In vitro expanded NK cells are highly cytotoxic against cancer cells. However, they lose this ability upon injection in vivo. TGF-β is produced by neutrophils, macrophages, and Tregs in the TME. Tregs and immunosuppressive myeloid-derived suppressor cells (MDSCs) are actively recruited to the TME to create a strong immunosuppressive environment promoting tumor growth [156]. Several strategies to minimize inhibitory effects of TGF-β have been reported. Administration of TGF-β kinase inhibitors along with NK cells preserves the cytotoxic potential and expression of activating NK receptors NKG2D and CD16 [157]. Use of fresolimumab, a TGF-β neutralizing antibody, and galunisertib, an inhibitor of TGF-βRI, have been reported as safe and tolerable in solid tumors in humans [158]. Hybrid CARs with an extracellular TGF-β receptor domain linked to an intracellular NKG2D domain enhance anti-tumor activity in NK-92 cells and knocking down SMAD3, the downstream mediator of TGF-β, in NK cells improves cytotoxicity in solid tumors [75, 159]. UCB NK cells expressing a dominant-negative TGF-β receptor retain their capacity to secrete IFN-γ and kill glioblastoma cells in the presence of TGF-β. Entinostat, a narrow spectrum histone deacetylase inhibitor, increases MICA expression on tumor cells and NKG2D expression in primary NK cells even in hypoxic conditions, leading to enhancement of cytotoxicity of NK cells against tumor cells [160]. It enhances both tumor cell recognition and killing. Immunosuppression in the TME due to metabolic disturbances The TME additionally suffers from hypoxia and nutrient depletion leading to acidosis, which further suppresses immune responses [156]. Hypoxia supports tumor growth by inducing metabolic disturbances and increasing angiogenesis and expression of tumor growth factors. In addition, it downregulates expression of NK cell activating receptors NKp30, NKp46, NKp44, and NKG2D for optimal tumor growth and metastasis [161]. CD73 induces expression of arginase, an immunosuppressive metabolite. Arginase is produced under hypoxic conditions and inhibits NK cell functions. CD73 inhibition increases homing of NKG2D-CAR NK cells, which target tumor cells expressing NKG2D liagnds, to the tumor site and improves anti-tumor responses in animal models for lung cancer [162]. Immunosuppression in the TME due to checkpoints Tumor cells evade immune surveillance through expression of checkpoint proteins that prevent immune cell activation. TIGIT inhibits NK cell cytotoxicity by opposing CD226 [163]. PD-1 + NK cells show reduced proliferation and effector functions, whereas PD-L1 + NK cells possess better effector functions [164]. Inhibition of PD-1 or PD-L1 using checkpoint blocking agents reactivates exhausted immune cells and achieves durable clinical responses [165]. Combining CARs with blockers of checkpoint proteins such as PD-1, CTLA-4, LAG3, and TIGIT has the potential to achieve persistent therapeutic benefits [145]. NK-92 cells engineered to express high-affinity CD16, IL-2, and a PD-L1-specific CAR contain high levels of perforin and granzyme and lyse human cancer cell lines including breast, lung, and gastric cancers [166]. Efforts to build more efficient CARs Although CAR NK cells and CAR T cells have opened a new era in immunotherapy, results from clinical studies suggest that improvement is still needed. Key areas that need further attention for improvement include modifying CAR structure for better efficiency and/or suitability to the TME, over-expressing activating and/or blocking inhibitory receptors on NK cells, improving cytotoxic mechanisms involving death receptors or granule-dependent pathways, and/or use of multiple compounds to increase CAR efficacy. Efforts to optimize CAR NK cell efficacy are extensive but can be categorized into the groups below: CARs targeting multiple proteins Some of the recent CAR NK-92 constructs include TCR-CARs created by fusing the extracellular domain of TCR (both TCRα and TCRβ) to a CAR-signaling tail composed of CD28 and CD3ζ signaling domains to enable the cells to recognize an array of targets, possibly some of the proteins presented on the MHC molecules, rather than a single TAA [167]. Expression of TCR-CAR in NK-92 cells grafts the cells with target recognition specificity of TCRs. This design has the potential of allowing the CAR NK-92 cells to target the proteome derived from tumor cells [167]. It would be interesting to determine whether this approach would work in primary NK cells or NK cells from other sources. CAR-modified immune cells secreting enzymes, interleukins, or chemokines “Armored” CAR design involves expressing cytokines, chemokines, or their receptors in CAR-modified immune cells to respond to threats from the TME or protect the CAR-bearing cells from immune suppression. CAR T cells expressing enzymes such as catalase, which can convert H2O2 into harmless by-products, or cytokines such as IL-15 have been developed [168]. CAR NK cells secreting autocrine IL-2 and IL-15 and silencing inhibitory KIRs have improved in vivo persistence [169]. CARs specific for various CC chemokines and/or their receptors have been reviewed above in the section on “Limited CAR trafficking and infiltration into tumor sites”. Converter CARs While some CARs provide the immune cells with more “armors” against the hostile tumor cells or the TME, others have been designed to “convert” the hostile actions into desirable effector functions. This “converter” design includes combining ecto- and endodomains of different molecules that graft specificity of the former coupled with the signaling capacity of the latter onto the immune cell. For example, CARs that combine ectodomain of IL-4 with the endodomain of IL-7 convert the inhibitory effects of IL-4 in the TME into the proliferative actions of IL-7 [170]. Similarly, CARs converting immunosuppressive effects of TGF-β into activating functions of NKG2D by fusing the extracellular and transmembrane portions of TGF-βRII and the intracellular domains of NKG2D, an activating receptor, have been reported [171]. Other variants of converter CARs include double chimeric design that involves introducing two CARs with different scFvs but the same intracellular signaling domain (dual-signaling CAR) [172]. A recent study sought to interfere with PD-1 signaling to reverse immunosuppression by PD-1 [173]. The authors fused the extracellular domain of PD-1, transmembrane and cytoplasmic domains of NKG2D, and the cytoplasmic domain of 4-1BB to create a chimeric co-stimulatory converting receptor-NK-92 cell line that reversed the inhibitory PD-1 signaling and increased anti-tumor activity against lung cancer cells [173]. Inducible CARs A fourth-generation CAR, also called TRUCK, has been developed [172]. In this design, inducible IL-12 is expressed only after encounter with the tumor specific antigens. IL-12 release activates innate immune cells that kill tumor cells carrying the specific antigen targeted by CAR. A form of TRUCK activated by inducible HIF1α in the TME has been reported [61]. Inducible expression of CAR can also be achieved using an injectable drug. A version of inducible CARs also termed “trans-signaling CARs” has been developed. These designs are especially useful in increasing safety and specificity of CARs when multiple proteins or isoforms of the same protein are targeted. Such CARs may engage antigens when either of multiple isoforms is available to increase range of efficacy or may require binding to all isoforms of the target for activation for increased specificity [172]. Modification of CARs using the CRISPR/Cas9 system Recent advances in CRISPR/Cas9 technology provide additional opportunities by enabling researchers to insert a CAR permanently into a desired position in the genome rather than insertion into random locations employed by most of the current viral transduction methods [174]. Another advantage of the CRISPR/Cas9 system is that it can be used to screen the whole genome in loss-of-function studies to reveal genomic regions or pathways important in mediating CAR toxicity. This approach has identified FADD and TNFRSF10B (TRAIL-R2) in CAR T cells but has not yet been studied in CAR NK cells [175]. Simultaneous administration of compounds to regulate these pathways can improve CAR effector functions. The CRISPR/Cas9 technology holds great promise in advancing the CAR NK cell research through boosting effector functions, especially for iPSC-derived CAR NK cells [89]. It can be used to knock out several genes simultaneously [176]. It is especially advantageous to use in modifying NK cells due to the fact that NK cell activation is achieved through a balance between inhibitory and activating signals. This technology can knock-in activating while simultaneously knocking-out inhibitory signals. It is known that viral integration rates are higher in genomic regions with active transcription or highly accessible chromatin [177]. The CRISPR/Cas9 system can be used to insert a CAR cassette into these regions to generate stably transduced primary NK cells, improving both efficacy and safety of CAR NK cells [61]. CRISPR/Cas9 has already been used to “knock-in” a CAR while simultaneously “knocking-out” endogenous elements such as components of the TCR that may interfere with the CAR functions in CAR T cells [178, 179]. Only few CRISPR/Cas9 studies have been conducted using NK cells possibly because NK cells are more difficult to transduce [180]. Two studies that successfully transfected NK cells with Cas9 protein and target-site-specific gRNA or DNA with homology to sequences flanking DNA double strand breaks using electroporation have been reviewed elsewhere [180]. In one of those studies, 60% and 34% reduction at the mRNA and protein level, respectively, in TGF-βR II expression was achieved [181]. Another study improved post-transduction survival up to 80% while maintaining efficient reduction in Ptprc gene expression [182]. This study additionally revealed that both homo- and heterozygous deletion of the gene of interest are possible in the same reaction. Despite the low number of studies reporting CAR NK cells created using the CRISPR/Cas9 technology, multiplex knockout of three genes (TRAC, B2M, and PD-1) in CD19-CAR T cells has already been achieved [183]. However, low knock-out rates for PD-1 were reported in that study. Another recent study was successful in efficiently knocking out PD-1 in CAR T cells targeting EGFRvIII [184]. The disruption did not change T cell phenotype or expression of other checkpoint receptors and enhanced activity of the CAR T cells. TGF-βR II has also been knocked out in CAR T cells, resulting in decreased T cell exhaustion [185]. Use of CARs along with monoclonal antibodies, nanoparticles, or chemical compounds for increased efficacy NK cells can be used in tandem with antibodies, radiation, chemotherapy [186], romidepsin, a histone deacetylase inhibitor, nanoparticles [187, 188], and/or cabozantinib, a tyrosine kinase inhibitor [189]. Romidepsin improves efficacy of CD20-CAR NK cells [187], and cabozantinib enhances effects of CAR NK-92 directed against EGFR [189]. Use of CAR NK cells along with monoclonal antibodies widely used in cancer immunotherapy represents an interesting field of research. Bi- and tri-specific killer cell engagers (BiKEs and TriKEs) have been used to improve NK cell anti-tumor activity via the CD16 (FcγRIII) receptor on NK cells [190]. A majority of NK cells express CD16 that enables them to kill tumor cells opsonized by therapeutic monoclonal antibodies such as rituximab through ADCC [191]. An excellent review on potential of NK cells in combination therapy with monoclonal antibodies is available elsewhere [192]. CAR-engineered hematopoietic stem cells CAR-engineered stem cells represent a viable option to eradicate viral infections or cancers as they can differentiate into CAR T cells or CAR NK cells. Hematopoietic stem/progenitor cell (HSPC) populations transfected with a CAR against HIV provide long-term immunity against HIV infections [193]. The CAR-stem cells differentiated into functional NK and T cells and suppressed HIV replication in vivo and in vitro. Since stem cells are self-renewing, these CAR-modified immune cells may lead to permanent remission [194]. This method has implications for transplantation studies and immunity against viral infections in addition to cancer immunotherapy. Protocols for generating NK cells through differentiation of genetically modified hematopoietic stem cells have already been developed [195]. Optimization of CAR signaling domain Incorporation of 4-1BB, a surface protein expressed by NK and activated T-cells, improves NK cell cytotoxicity and IFNγ production [93, 94]. Although not expressed in NK cells, CD28 is commonly incorporated into CAR design for NK cells to amplify extracellular signaling. NK-92 cells carrying CARs with CD28/CD3ζ and 4-1BB/CD3ζ signaling domains have stronger cytotoxicity than CARs with only CD3ζ in killing HER2-expressing breast carcinoma cells [107]. Stimulation with 4-1BB is more effective than CD28 in expanding CD8+ T cells, and it has been shown that incorporation of both CD28 and 4-1BB co-stimulatory domains improves in vivo persistence in CAR T cells [196]. Additional potential co-stimulatory molecules being explored in CAR design for NK cells include 2B4 (CD224), DAP10, and DAP12 [94, 113, 140, 197]. Although 2B4 signaling alone only weakly induces NK cell activation, CARs including 2B4 along with CD3ζ enhance all aspects of the NK cell activation against leukemia and neuroblastoma cells [113]. Additionally, CARs utilizing a signaling domain for DAP12, which is involved in signal transduction of activating receptors such as NKG2C, NKp44, and KIR3DS1 [198, 199], exhibit improved NK cell cytotoxicity compared to CARs with CD3ζ as the sole signaling domain [140]. Manipulation of immunologic synapse formation and NK cell subsets Immunologic synapse formation by CAR NK cells and possible differences in CAR production efficiency among different subtypes of NK cells have not been fully investigated in the literature. Synapse formation is a step-wise process that involves distribution, rearrangement and clustering of signaling molecules, F-actin, and tumor antigens at the site of contact. Synapse formation between NK cells and various target cells has been extensively investigated [200]. The NK IS formation involves central and peripheral supramolecular activation cluster (SMAC). The central and peripheral SMACs involve actions by distinct sets of proteins. The central domain includes mostly perforin, whereas the peripheral domain consists of surface receptors and F-actin. Upon stimulation, surface receptors including CD2, CD11a, CD11b, and F-actin rapidly accumulate at peripheral SMAC. This accumulation is dependent on actin polymerization driven by Wiskott–Aldrich syndrome protein. Accumulation of perforin at central SMAC is, on the other hand, slow and appears only after peripheral SMAC activation. The strong need for studying IS formation in CAR NK cells as well as critical steps of IS formation during the killing of target cells by NK cells has been reviewed elsewhere [201]. Similarities and differences between the conventional and CAR NK cell signaling events occurring at IS have not been well understood. A better understanding and possible manipulation of the IS formation can significantly improve CAR efficacy [201] because IS is critical for successful elimination of the target [202]. During natural T cell receptor activation, CD4/CD8 T cells interact with MHC molecules on antigen presenting cells (APCs) resulting in activation of Lck which then phosphorylates ZAP70, resulting in signal 1 for T cell activation. Signal 2 required for activation is a result of CD28 on T cells interacting with CD80/CD86 on APCs creating an IS with a 15-nm gap [203]. The 15-nm distance physically excludes other inhibitory molecules such as CD45 with large domains from entering into IS. It is unknown whether these processes occur similarly at IS formed between the CAR NK cells and their targets. Studying different NK cell subsets carrying the same CAR may reveal subtypes more efficient than others for specific purposes [204]. It is estimated that there are 6000–30,000 different NK cell phenotypes in a healthy donor due to the high number of activating receptors with different functions expressed at different stages of development [138]. However, only limited data are available on the characteristics of these subtypes of NK cells. Enhancement of CAR NK cell activation and proliferation by cytokines NK cells in patients with tumors are often functionally impaired and live shorter than those in healthy individuals. Cytokines, or their analogs with longer in vivo half-life, can be used to increase NK cell activation, proliferation, trafficking, and persistence. Effects of several cytokines including IL-2, IL-12, IL-15, IL-18, and IL-21 on NK cell function have been reviewed in detail elsewhere [75]. The cytokines can be administered in vivo or used for in vitro stimulation before adoptive cell transfer. NK cells require IL-2 or IL-15 for optimal growth. NK-92MI, an NK-92 cell line constitutively expressing IL-2, has been generated [114, 143]. IL-2 and IL-15 are both included in the γ chain family of cytokines and share some common functions [114]. Co-expressing IL-15 and an EpCAM CAR in NK-92 cells resulted in a predominant intracellular acculmulation of the cytokine and selection of CAR-bearing cells upon IL-2 withdrawal, which eliminated all but the transduced NK-92 cells. These CAR NK cells successfully lysed breast cancer cells in the absence of any other cytokine [114]. IL-2 is safe to administer in lung cancer patients and induces proliferation and cytotoxic capacity in NK cells, but it also attracts and stimulates immunosuppressive Tregs at high doses [205]. IL-15 may be more effective in improving NK cell function because it is anti-neoplastic, more potent than IL-2, and does not attract Tregs. CAR NK cells may be stimulated by IL-15 through co-culturing with feeder K562 cells expressing membrane-bound IL-15 and 4-1BB ligand [94]. Co-culturing PB NK cells with K562-based feeder cells expressing membrane-bound IL-21 significantly improves NK cell expansion in vitro. IL-12 at the dose of 500 ng/kg/day was initially found safe in a phase 1 clinical trial. However, the same dose resulted in serious side effects in 12 of 17 patients enrolled in the study and two patients died, leading to a ban by the FDA on all clinical trials involving IL-12 [206]. CAR NK activation and proliferation through manipulation of NK cell receptors NK cell effector functions can be improved through inhibiting inhibitory KIRs such as KIR2DL-1, -2, or -3 and/or overexpressing activating KIRs. Inhibitory receptors (as listed by Pockley et al. [205] with their ligands on tumor indicated in parentheses) include PD-1 (PD-L1), KIRs (HLA-C), LAG3 (MHC II), NKG2A/CD94 complex (HLA-E), TIGIT (CD155), TIM3 (Galectin-9), and KLRG-1 (E-cadherin), whereas activating NK receptors include NKG2D (MICA/B), KIRs (HLA-C), CD226 or DNAM-1 (CD112 or Nectin-2, CD155 or PVR), and NKG2C/CD94 complex (HLA-E and Hsp70). In addition, receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) have been identified on NK cells. 2B4 and CS1 regulate NK cell cytotoxicity, whereas LLT1 is additionally expressed in prostate and TNBC cells and plays a role in evading NK cell-mediated tumor cell killing [207]. One of the most studied NK cell receptors is NKG2D. Histone deacetylase inhibitors such as sodium valproate enhance NK-mediated cell killing by increasing expression of NKG2D ligands MHC class I chain-related molecules MICA and MICB on tumor cells [208]. Parihar et al. (2019) created CAR NK cells expressing a chimeric receptor in which NKG2D is fused to CD3ζ [209]. These CAR NK cells reduced tumor burden through killing intra-tumoral MDSCs that expressed high levels of NKG2D ligands and, unlike unmodified NK cells, released cytokines even in the TME. The CAR NK cells additionally improved CAR T cell trafficking to the tumor site through chemokine secretion. The authors concluded that these CAR NK cells should be used in combination with CAR T cells for optimum efficacy in the TME in solid tumors. Use of anti-KIR antibodies such as lirilumab to enhance in vivo CAR NK effector functions represents a novel approach in the treatment of solid tumors. Lirilumab is a fully human IgG4 mAb [210] that improves NK cell anti-tumor functions by inhibiting KIR2D subgroup [211] receptors on NK cells and blocking the repressive KIR-MHC interactions [210]. Lirilumab efficacy has been tested in enhancing NK effector functions in both liquid and solid tumors [210]. Lirilumab, in combination with ipilimumab, is being tested for treatment of advanced solid tumors in a clinical trial (NCT01750580), but the trial is still recruiting patients [212]. In vitro evidence suggests that lirilumab enhances killing of head and neck squamous cell carcinoma (HNSCC) cells by NK cells [213]. Enhancement of anti-tumoral effects of lirilumab, in combination with rituximab, has been well demonstrated in hematologic malignancies both in vivo and in vitro [214]. In myelodysplastic syndrome patients, lirilumab is effective both as a monotherapy and in combination with azacitidine although the authors cautioned that further studies are needed to confirm their findings [215]. IPH2101, a prior version of lirilumab that recognizes the same epitope, has also been tested in the clinic [216–218]. It will be interesting to determine if abrogation of KIR inhibitory signaling by KIR antibodies will further improve anti-tumor activity of CAR NK cells. Modifying cell metabolism to improve CAR NK effector functions Enhancing CAR NK cell activity in solid tumors through modulation of tumor metabolism has received little attention in the literature. Extracellular adenosine generated from ATP present in the hypoxic tumor environment through actions of CD39 and CD73 plays critical roles in immune evasion, inhibition of NK cell maturation, and suppression of NK cell trafficking to the tumor site [162]. Adenosine inhibition using anti-CD39 and anti-CD73 antibodies improves targeted therapy in ovarian cancer [219]. CD73 is highly expressed in several solid tumors including glioblastoma, prostate, and lung cancer, and its inhibition using neutralizing antibodies further improves therapeutic effects of NKG2D-engineered CAR NK cells in a mice model of lung cancer [162]. CAR NK cell clinical trials Currently, there are 19 CAR NK clinical trials available on ClinicalTrials.Gov website (Table 4). Eleven and eight trials have targeted liquid and solid tumors, respectively. The most common targets (with number of clinical trials in parentheses) are CD19 (7), ROBO1 (3), and CD22 (2). One clinical trial has been completed, eight have been recruiting patients, one is suspended, and one is withdrawn. Five trials have not begun recruiting patients, and the status of the remaining three trials is unknown. Five trials are at early phase 1, four at phase 1, and ten are at phase 1 or 2 stages. Fourteen of the trials originated from China, three from the USA, one from Singapore, and one from Germany.Table 4 Current CAR NK clinical trials listed on ClinicalTrials.Gov Tumor type Tumor type Target antigen NCT number Types of NK cells Status Phase Country ALL Liquid CD19 NCT00995137 Haploidentical donor NK cells Completed 1 USA Solid tumors Solid NKG2D ligands NCT03415100 Autologous or allogeneic CAR NK cells targeting NKG2D ligands Recruiting 1 China B-lymphoid malignancy, ALL, CLL, lymphoma Liquid CD19 NCT03056339 UCB NK cells Recruiting 1/2 USA Multiple myeloma Liquid BCMA NCT03940833 NK-92 cells Recruiting 1/2 China Solid tumors Solid ROBO1 NCT03940820 Unclear Recruiting 1/2 China Pancreatic cancer Solid ROBO1 NCT03941457 Unclear Recruiting 1/2 China Solid tumors Solid ROBO1 NCT03931720 Unclear Recruiting 1/2 China Glioblastoma Solid HER2 NCT03383978 NK-92 cells Recruiting 1 Germany B-cell acute lymphoblastic leukemia Liquid CD19 NCT01974479 Haploidentical donor NK cells Suspended 1 Singapore AML Liquid CD33 NCT02944162 NK-92 cells Recruiting 1/2 China Mantle cell, follicular, and B-cell lymphoma Liquid CD19 NCT03579927 UCB NK cells Withdrawn 1/2 USA Refractory B-cell lymphoma Liquid CD22 NCT03692767 Unclear Not yet recruiting Early 1 China Refractory B-cell lymphoma Liquid CD19 NCT03690310 Unclear Not yet recruiting Early 1 China Ovarian cancer Solid Mesothelin NCT03692637 Unclear Not yet recruiting Early 1 China Prostate cancer Solid PSMA NCT03692663 Unclear Not yet recruiting Early 1 China Refractory B-cell lymphoma Liquid CD19, CD22 NCT03824964 Unclear Not yet recruiting Early 1 China ALL, CLL, mantle cell and follicular lymphoma Liquid CD19 NCT02892695 NK-92 cells Unknown 1/2 China ALL, T-cell leukemia and lymphoma Liquid CD7 NCT02742727 NK-92 cells Unknown 1/2 China Hepatic, lung, pancreas, breast, colon, and gastric cancer Solid MUC1 NCT02839954 Unclear Unknown 1/2 China In one of those studies, a phase 1/2 trial (NCT02944162) targeting CD33 in AML patients had three patients who were administered nearly five billion irradiated CD33-CAR NK-92 cells. Although therapeutic response was limited, the patients did not show any significant adverse reactions after administration of up to five billion NK-92 cells, suggesting that injection of a large number of NK-92 cells may be safe [67]. A recent promising phase 1/2 clinical trial in the USA (NCT03056339) is being conducted to investigate the safety and efficacy of primary NK cells obtained from UCB carrying a CD19-CD28-CD3ζ-2A-iCasp9-IL15 construct in patients with relapsed/refractory B-cell ALL, CLL, and non-Hodgkin lymphoma. The CAR NK treatment was carried out in conjunction with lymphodepleting chemotherapy. Very encouraging results from this trial have recently been published [68]. As summarized above, eight of the 11 patients responded to the therapy. Importantly, NK cells persisted in patients for over 12 months possibly due to the incorporation of IL-15 in the CAR vector. A clinical trial being conducted in Germany has been investigating the safety and tolerability of NK-92 cells carrying anti-HER2 CAR in glioblastoma patients (NCT03383978). Conclusions CAR-engineered T cells have already achieved impressive responses in treating some hematologic malignancies. NK cells offer an additional advantage in that they may not require any immunological matching between donor and patients and thus have the potential for developing “off-the-shelf” products for cancer immunotherapy. Although some challenges still exist, the recent success involving CD19-CAR NK cells expressing IL-15 [68] suggests that a broader application and advancement in using “off-the-shelf” CAR NK cell products for the treatment of hematologic malignancies and solid tumors may occur in the near future. Abbreviations ADCCAntibody-dependent cellular cytotoxicity ALLAcute lymphoblastic leukemia AMLAcute myeloid leukemia APCAntigen presenting cell CARChimeric antigen receptor CCLCC chemokine ligand CCRCC chemokine receptor CLLChronic lymphocytic leukemia CRComplete remission CRiComplete remission with incomplete hematologic recovery CRSCytokine release syndrome CSCCancer stem cell-like cell DLBCLDiffuse large B-cell lymphoma FasLFas ligand FDAUS Food and Drug Administration GM-CSFGranulocyte-macrophage colony stimulating factor GvHDGraft vs. host disease HLAHuman leukocyte antigen HNSCCHead and neck squamous cell carcinoma HSPCHematopoietic stem/progenitor cell IFN-γInterferon-γ IL-2DTIL-2 diphtheria toxin fusion protein ILCInnate lymphoid cell iPSCInduced pluripotent stem cell ISImmunologic synapse ITAMImmunoreceptor tyrosine-based activation motif ITTIntent-to-treatment KIRKiller immunoglobulin receptor L-ICONAntibody-like immunoconjugates MDSCMyeloid-derived suppressor cell MMMultiple myeloma MOIMultiplicity of infection NCRNatural cytotoxicity receptor NEP3D nanochannel-electroporation NKNatural killer NSGNOD scid gamma oHSV-1Herpes simplex virus 1-based oncolytic virus ORROverall remission rate PBPeripheral blood PSMAProstate-specific membrane antigen PSCAProstate stem cell antigen RAGRecombination activating gene RCCRenal cell carcinoma RT-PCRReal-time PCR scFvSingle-chain antibody variable fragment SMACSupramolecular activation cluster TAATumor-associated antigen TCRT cell receptor TFTissue factor TGF-βTransforming growth factor-beta TMETumor microenvironment TNBCTriple-negative breast cancer TRAILTNF-related apoptosis-inducing ligand UCBUmbilical cord blood Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. All authors contributed equally to this work Acknowledgements The authors regret that it was not possible to include many interesting studies in the field due to limited space. Authors’ contributions All authors wrote and revised the initial draft, finalized the last version of the article, and approved the final version. Funding This work was supported by grants from the NIH (AI129582, CA247550, NS106170, CA223400, CA210087, CA068458, and CA163205), the Leukemia & Lymphoma Society (6503-17 and 1364-19), and the California Institute for Regenerative Medicine (DISC2COVID19-11947). Availability of data and materials Not applicable. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests M.A. Caligiuri and J. Yu are the co-founders of CytoImmune Therapeutics, Inc. The other authors declare no competing interests. ==== Refs References 1. Spits H Artis D Colonna M Diefenbach A Di Santo JP Eberl G Koyasu S Locksley RM McKenzie AN Mebius RE Innate lymphoid cells–a proposal for uniform nomenclature Nat Rev Immunol 2013 13 2 145 149 10.1038/nri3365 23348417 2. Ishizuka IE Constantinides MG Gudjonson H Bendelac A The innate lymphoid cell precursor Annu Rev Immunol 2016 34 299 316 10.1146/annurev-immunol-041015-055549 27168240 3. Walker JA Barlow JL McKenzie AN Innate lymphoid cells—how did we miss them? Nat Rev Immunol 2013 13 2 75 87 10.1038/nri3349 23292121 4. Vivier E Tomasello E Baratin M Walzer T Ugolini S Functions of natural killer cells Nat Immunol 2008 9 5 503 510 10.1038/ni1582 18425107 5. Yu J Freud AG Caligiuri MA Location and cellular stages of natural killer cell development Trends Immunol 2013 34 12 573 582 10.1016/j.it.2013.07.005 24055329 6. Freud AG Mundy-Bosse BL Yu J Caligiuri MA The broad spectrum of human natural killer cell diversity Immunity 2017 47 5 820 833 10.1016/j.immuni.2017.10.008 29166586 7. Farag SS Caligiuri MA Human natural killer cell development and biology Blood Rev 2006 20 3 123 137 10.1016/j.blre.2005.10.001 16364519 8. Hesslein DG Lanier LL Transcriptional control of natural killer cell development and function Adv Immunol 2011 109 45 85 10.1016/B978-0-12-387664-5.00002-9 21569912 9. Di Santo JP Natural killer cell developmental pathways: a question of balance Annu Rev Immunol 2006 24 257 286 10.1146/annurev.immunol.24.021605.090700 16551250 10. Mehta RS Rezvani K Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer Front Immunol 2018 9 283 10.3389/fimmu.2018.00283 29497427 11. Lanier LL NK cell recognition Annu Rev Immunol 2005 23 225 274 10.1146/annurev.immunol.23.021704.115526 15771571 12. Moretta A Marcenaro E Parolini S Ferlazzo G Moretta L NK cells at the interface between innate and adaptive immunity Cell Death Differ 2008 15 2 226 233 10.1038/sj.cdd.4402170 17541426 13. Morvan MG Lanier LL NK cells and cancer: you can teach innate cells new tricks Nat Rev Cancer 2016 16 1 7 19 10.1038/nrc.2015.5 26694935 14. Klingemann H Boissel L Toneguzzo F Natural killer cells for immunotherapy—advantages of the NK-92 cell line over blood NK cells Front Immunol 2016 7 91 10.3389/fimmu.2016.00091 27014270 15. Waldhauer I Steinle A NK cells and cancer immunosurveillance Oncogene 2008 27 45 5932 5943 10.1038/onc.2008.267 18836474 16. Ljunggren HG Malmberg KJ Prospects for the use of NK cells in immunotherapy of human cancer Nat Rev Immunol 2007 7 5 329 339 10.1038/nri2073 17438573 17. Hervieu A Rébé C Végran F Chalmin F Bruchard M Vabres P Apetoh L Ghiringhelli F Mignot G Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth J Invest Dermatol 2013 133 2 499 508 10.1038/jid.2012.273 22951720 18. Childs RW Carlsten M Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens Nat Rev Drug Discov 2015 14 7 487 498 10.1038/nrd4506 26000725 19. Mailliard RB Son YI Redlinger R Coates PT Giermasz A Morel PA Storkus WJ Kalinski P Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function J Immunol 2003 171 5 2366 2373 10.4049/jimmunol.171.5.2366 12928383 20. Delneste Y Charbonnier P Herbault N Magistrelli G Caron G Bonnefoy JY Jeannin P Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages Blood 2003 101 1 143 150 10.1182/blood-2002-04-1164 12393446 21. Cheng M Chen Y Xiao W Sun R Tian Z NK cell-based immunotherapy for malignant diseases Cell Mol Immunol 2013 10 3 230 252 10.1038/cmi.2013.10 23604045 22. Han J Alvarez-Breckenridge CA Wang QE Yu J TGF-β signaling and its targeting for glioma treatment Am J Cancer Res 2015 5 3 945 955 26045979 23. Salih HR Rammensee HG Steinle A Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding J Immunol 2002 169 8 4098 4102 10.4049/jimmunol.169.8.4098 12370336 24. Lichtenegger FS Krupka C Haubner S Kohnke T Subklewe M Recent developments in immunotherapy of acute myeloid leukemia J Hematol Oncol 2017 10 1 142 10.1186/s13045-017-0505-0 28743264 25. Hegde PS Chen DS Top 10 challenges in cancer immunotherapy Immunity 2020 52 1 17 35 10.1016/j.immuni.2019.12.011 31940268 26. Grupp SA Kalos M Barrett D Aplenc R Porter DL Rheingold SR Teachey DT Chew A Hauck B Wright JF Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 2013 368 16 1509 1518 10.1056/NEJMoa1215134 23527958 27. Sadelain M Riviere I Brentjens R Targeting tumours with genetically enhanced T lymphocytes Nat Rev Cancer 2003 3 1 35 45 10.1038/nrc971 12509765 28. Brown CE Alizadeh D Starr R Weng L Wagner JR Naranjo A Ostberg JR Blanchard MS Kilpatrick J Simpson J Regression of glioblastoma after chimeric antigen receptor T-cell therapy N Engl J Med 2016 375 26 2561 2569 10.1056/NEJMoa1610497 28029927 29. Fernandez L Metais JY Escudero A Vela M Valentin J Vallcorba I Leivas A Torres J Valeri A Patino-Garcia A Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells Clin Cancer Res 2017 23 19 5824 5835 10.1158/1078-0432.CCR-17-0075 28659311 30. Irving BA Weiss A The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways Cell 1991 64 5 891 901 10.1016/0092-8674(91)90314-O 1705867 31. Sadelain M Brentjens R Riviere I The basic principles of chimeric antigen receptor design Cancer Discov 2013 3 4 388 398 10.1158/2159-8290.CD-12-0548 23550147 32. Dotti G Gottschalk S Savoldo B Brenner MK Design and development of therapies using chimeric antigen receptor-expressing T cells Immunol Rev 2014 257 1 107 126 10.1111/imr.12131 24329793 33. Jackson HJ Rafiq S Brentjens RJ Driving CAR T-cells forward Nat Rev Clin Oncol 2016 13 6 370 383 10.1038/nrclinonc.2016.36 27000958 34. Gill S Maus MV Porter DL Chimeric antigen receptor T cell therapy: 25years in the making Blood Rev 2016 30 3 157 167 10.1016/j.blre.2015.10.003 26574053 35. Ramos CA Heslop HE Brenner MK CAR-T cell therapy for lymphoma Annu Rev Med 2016 67 165 183 10.1146/annurev-med-051914-021702 26332003 36. Jain MD Davila ML Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell malignancies Stem Cells (Dayton, OH) 2018 36 1 36 44 10.1002/stem.2715 37. Watanabe K Terakura S Martens AC van Meerten T Uchiyama S Imai M Sakemura R Goto T Hanajiri R Imahashi N Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells J Immunol 2015 194 3 911 920 10.4049/jimmunol.1402346 25520398 38. Zhang C Liu J Zhong JF Zhang X Engineering CAR-T cells Biomark Res 2017 5 22 10.1186/s40364-017-0102-y 28652918 39. Hambach J Riecken K Cichutek S Schütze K Albrecht B Petry K Röckendorf JL Baum N Kröger N Hansen T Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs) Cells 2020 9 2 321 10.3390/cells9020321 40. Hoseini SS Cheung NK Acute myeloid leukemia targets for bispecific antibodies Blood Cancer J 2017 7 4 e552 10.1038/bcj.2017.35 28409770 41. Stoiber S Cadilha BL Benmebarek MR Lesch S Endres S Kobold S Limitations in the design of chimeric antigen receptors for cancer therapy Cells 2019 8 5 472 10.3390/cells8050472 42. van der Stegen SJ Hamieh M Sadelain M The pharmacology of second-generation chimeric antigen receptors Nat Rev Drug Discov. 2015 14 7 499 509 10.1038/nrd4597 26129802 43. Fernandez L Fernandez A Mirones I Escudero A Cardoso L Vela M Lanzarot D de Paz R Leivas A Gallardo M GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS prodigy Front Immunol 2019 10 2361 10.3389/fimmu.2019.02361 31649672 44. Chu J Deng Y Benson DM He S Hughes T Zhang J Peng Y Mao H Yi L Ghoshal K CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma Leukemia 2014 28 4 917 927 10.1038/leu.2013.279 24067492 45. Guedan S Calderon H Posey AD Jr Maus MV Engineering and design of chimeric antigen receptors Mol Therapy Methods Clin Dev 2019 12 145 156 10.1016/j.omtm.2018.12.009 46. Porter DL Hwang WT Frey NV Lacey SF Shaw PA Loren AW Bagg A Marcucci KT Shen A Gonzalez V Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Sci Transl Med 2015 7 303 303ra139 10.1126/scitranslmed.aac5415 26333935 47. Lee DW Kochenderfer JN Stetler-Stevenson M Cui YK Delbrook C Feldman SA Fry TJ Orentas R Sabatino M Shah NN T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 2015 385 9967 517 528 10.1016/S0140-6736(14)61403-3 25319501 48. Maude SL Frey N Shaw PA Aplenc R Barrett DM Bunin NJ Chew A Gonzalez VE Zheng Z Lacey SF Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 2014 371 16 1507 1517 10.1056/NEJMoa1407222 25317870 49. O’Leary M. Biologic License Application Clinical Review Memorandum. Biologics license application 2017:12. 50. Gorovits B Koren E Immunogenicity of chimeric antigen receptor T-cell therapeutics BioDrugs 2019 33 3 275 284 10.1007/s40259-019-00354-5 31069709 51. Kurlander R. Approval of CD19-directed CAR T cells: FDA licensure of new cell-based gene therapy products with a challenging safety profile. FDA clinical review memorandum 2017:9. 52. Lamers CH Sleijfer S van Steenbergen S van Elzakker P van Krimpen B Groot C Vulto A den Bakker M Oosterwijk E Debets R Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity Mol Therapy 2013 21 4 904 912 10.1038/mt.2013.17 53. Kershaw MH Westwood JA Parker LL Wang G Eshhar Z Mavroukakis SA White DE Wunderlich JR Canevari S Rogers-Freezer L A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 2006 12 20 Pt 1 6106 6115 10.1158/1078-0432.CCR-06-1183 17062687 54. Craddock JA Lu A Bear A Pule M Brenner MK Rooney CM Foster AE Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b J Immunother 2010 33 8 780 788 10.1097/CJI.0b013e3181ee6675 20842059 55. Stern LA Jonsson VD Priceman SJ CAR T cell therapy progress and challenges for solid tumors Cancer Treat Res 2020 180 297 326 10.1007/978-3-030-38862-1_11 32215875 56. Lee DW Gardner R Porter DL Louis CU Ahmed N Jensen M Grupp SA Mackall CL Current concepts in the diagnosis and management of cytokine release syndrome Blood 2014 124 2 188 195 10.1182/blood-2014-05-552729 24876563 57. Bonifant CL Jackson HJ Brentjens RJ Curran KJ Toxicity and management in CAR T-cell therapy Mol Therapy Oncolyt 2016 3 16011 10.1038/mto.2016.11 58. Davila ML Riviere I Wang X Bartido S Park J Curran K Chung SS Stefanski J Borquez-Ojeda O Olszewska M Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 2014 6 224 224ra225 10.1126/scitranslmed.3008226 59. Morgan RA Yang JC Kitano M Dudley ME Laurencot CM Rosenberg SA Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Therapy 2010 18 4 843 851 10.1038/mt.2010.24 60. Hirayama AV Turtle CJ Toxicities of CD19 CAR-T cell immunotherapy Am J Hematol 2019 94 S1 S42 s49 10.1002/ajh.25445 30784102 61. Hu Y Tian ZG Zhang C Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy Acta Pharmacol Sin 2018 39 2 167 176 10.1038/aps.2017.125 28880014 62. Miller JS Soignier Y Panoskaltsis-Mortari A McNearney SA Yun GH Fautsch SK McKenna D Le C Defor TE Burns LJ Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 2005 105 8 3051 3057 10.1182/blood-2004-07-2974 15632206 63. Olson JA Leveson-Gower DB Gill S Baker J Beilhack A Negrin RS NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects Blood 2010 115 21 4293 4301 10.1182/blood-2009-05-222190 20233969 64. Graham C Jozwik A Pepper A Benjamin R Allogeneic CAR-T cells: more than ease of access? Cells 2018 7 10 155 10.3390/cells7100155 65. Klingemann H Are natural killer cells superior CAR drivers? Oncoimmunology 2014 3 e28147 10.4161/onci.28147 25340009 66. Glienke W Esser R Priesner C Suerth JD Schambach A Wels WS Grez M Kloess S Arseniev L Koehl U Advantages and applications of CAR-expressing natural killer cells Front Pharmacol 2015 6 21 10.3389/fphar.2015.00021 25729364 67. Tang X Yang L Li Z Nalin AP Dai H Xu T Yin J You F Zhu M Shen W First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia Am J Cancer Res 2018 8 6 1083 1089 30034945 68. Liu E Marin D Banerjee P Macapinlac HA Thompson P Basar R Nassif Kerbauy L Overman B Thall P Kaplan M Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors N Engl J Med 2020 382 6 545 553 10.1056/NEJMoa1910607 32023374 69. Cheng M Zhang J Jiang W Chen Y Tian Z Natural killer cell lines in tumor immunotherapy Front Med 2012 6 1 56 66 10.1007/s11684-012-0177-7 22460449 70. Tonn T Schwabe D Klingemann HG Becker S Esser R Koehl U Suttorp M Seifried E Ottmann OG Bug G Treatment of patients with advanced cancer with the natural killer cell line NK-92 Cytotherapy 2013 15 12 1563 1570 10.1016/j.jcyt.2013.06.017 24094496 71. Klingemann H Challenges of cancer therapy with natural killer cells Cytotherapy 2015 17 3 245 249 10.1016/j.jcyt.2014.09.007 25533934 72. MacLeod RA Nagel S Kaufmann M Greulich-Bode K Drexler HG Multicolor-FISH analysis of a natural killer cell line (NK-92) Leuk Res 2002 26 11 1027 1033 10.1016/S0145-2126(02)00055-3 12363472 73. Hermanson DL Kaufman DS Utilizing chimeric antigen receptors to direct natural killer cell activity Front Immunol 2015 6 195 10.3389/fimmu.2015.00195 25972867 74. Messaoudene M Frazao A Gavlovsky PJ Toubert A Dulphy N Caignard A Patient's natural killer cells in the era of targeted therapies: role for tumor killers Front Immunol 2017 8 683 10.3389/fimmu.2017.00683 28659921 75. Nayyar G Chu Y Cairo MS Overcoming resistance to natural killer cell based immunotherapies for solid tumors Front Oncol 2019 9 51 10.3389/fonc.2019.00051 30805309 76. Luevano M Daryouzeh M Alnabhan R Querol S Khakoo S Madrigal A Saudemont A The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation Hum Immunol 2012 73 3 248 257 10.1016/j.humimm.2011.12.015 22234167 77. Kotylo PK Baenzinger JC Yoder MC Engle WA Bolinger CD Rapid analysis of lymphocyte subsets in cord blood Am J Clin Pathol 1990 93 2 263 266 10.1093/ajcp/93.2.263 2301287 78. Rocha V Labopin M Sanz G Arcese W Schwerdtfeger R Bosi A Jacobsen N Ruutu T de Lima M Finke J Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia N Engl J Med 2004 351 22 2276 2285 10.1056/NEJMoa041469 15564544 79. Eapen M Rubinstein P Zhang MJ Stevens C Kurtzberg J Scaradavou A Loberiza FR Champlin RE Klein JP Horowitz MM Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study Lancet 2007 369 9577 1947 1954 10.1016/S0140-6736(07)60915-5 17560447 80. Atsuta Y Suzuki R Nagamura-Inoue T Taniguchi S Takahashi S Kai S Sakamaki H Kouzai Y Kasai M Fukuda T Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia Blood 2009 113 8 1631 1638 10.1182/blood-2008-03-147041 19104080 81. Harris DT Schumacher MJ Locascio J Besencon FJ Olson GB DeLuca D Shenker L Bard J Boyse EA Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes Proc Natl Acad Sci USA 1992 89 21 10006 10010 10.1073/pnas.89.21.10006 1438190 82. Xing D Ramsay AG Gribben JG Decker WK Burks JK Munsell M Li S Robinson SN Yang H Steiner D Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion J Immunother 2010 33 7 684 696 10.1097/CJI.0b013e3181e475e9 20664358 83. Liu E Tong Y Dotti G Shaim H Savoldo B Mukherjee M Orange J Wan X Lu X Reynolds A Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity Leukemia 2018 32 2 520 531 10.1038/leu.2017.226 28725044 84. Woll PS Grzywacz B Tian X Marcus RK Knorr DA Verneris MR Kaufman DS Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity Blood 2009 113 24 6094 6101 10.1182/blood-2008-06-165225 19365083 85. Eguizabal C Zenarruzabeitia O Monge J Santos S Vesga MA Maruri N Arrieta A Rinon M Tamayo-Orbegozo E Amo L Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Front Immunol 2014 5 439 10.3389/fimmu.2014.00439 25309538 86. Knorr DA Ni Z Hermanson D Hexum MK Bendzick L Cooper LJ Lee DA Kaufman DS Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy Stem Cells Transl Med 2013 2 4 274 283 10.5966/sctm.2012-0084 23515118 87. Cany J van der Waart AB Tordoir M Franssen GM Hangalapura BN de Vries J Boerman O Schaap N van der Voort R Spanholtz J Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice PLoS ONE 2013 8 6 e64384 10.1371/journal.pone.0064384 23755121 88. Spanholtz J Preijers F Tordoir M Trilsbeek C Paardekooper J de Witte T Schaap N Dolstra H Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process PLoS ONE 2011 6 6 e20740 10.1371/journal.pone.0020740 21698239 89. Li Y Hermanson DL Moriarity BS Kaufman DS Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity Cell Stem Cell 2018 23 2 181 192.e185 10.1016/j.stem.2018.06.002 30082067 90. Shimasaki N Fujisaki H Cho D Masselli M Lockey T Eldridge P Leung W Campana D A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies Cytotherapy 2012 14 7 830 840 10.3109/14653249.2012.671519 22458956 91. Boissel L Betancur M Wels WS Tuncer H Klingemann H Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells Leuk Res 2009 33 9 1255 1259 10.1016/j.leukres.2008.11.024 19147228 92. Li L Liu LN Feller S Allen C Shivakumar R Fratantoni J Wolfraim LA Fujisaki H Campana D Chopas N Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method Cancer Gene Ther 2010 17 3 147 154 10.1038/cgt.2009.61 19745843 93. Imai C Mihara K Andreansky M Nicholson IC Pui CH Geiger TL Campana D Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 2004 18 4 676 684 10.1038/sj.leu.2403302 14961035 94. Imai C Iwamoto S Campana D Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells Blood 2005 106 1 376 383 10.1182/blood-2004-12-4797 15755898 95. Y C, A Y, J A, C V, M B, M C, MS C. Anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells significantly mediate rituximab sensitive and resistant burkitt lymphoma (BL) regression and improve survival in human BL xenografted NSG mice. Cytotherapy 2014, 16(4):S21. 96. Boissel L Betancur-Boissel M Lu W Krause DS Van Etten RA Wels WS Klingemann H Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity Oncoimmunology 2013 2 10 e26527 10.4161/onci.26527 24404423 97. Muller T Uherek C Maki G Chow KU Schimpf A Klingemann HG Tonn T Wels WS Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells Cancer Immunol Immunother CII 2008 57 3 411 423 10.1007/s00262-007-0383-3 17717662 98. Jiang H Zhang W Shang P Zhang H Fu W Ye F Zeng T Huang H Zhang X Sun W Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells Mol Oncol 2014 8 2 297 310 10.1016/j.molonc.2013.12.001 24388357 99. Hsi ED Steinle R Balasa B Szmania S Draksharapu A Shum BP Huseni M Powers D Nanisetti A Zhang Y CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin Cancer Res 2008 14 9 2775 2784 10.1158/1078-0432.CCR-07-4246 18451245 100. Zhang Y Chen L Wang Y Li X Hughes T Klingemann H Benson DM Yu J Combination therapy with daratumumab and CAR-NK targeting CS1 for multiple myeloma Blood Rev 2016 128 1342 10.1182/blood.V128.22.1342.1342 101. Clark EA Giltiay NV CD22: A regulator of innate and adaptive B cell responses and autoimmunity Front Immunol 2018 9 2235 10.3389/fimmu.2018.02235 30323814 102. De Propris MS Raponi S Diverio D Milani ML Meloni G Falini B Foà R Guarini A High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation Haematologica 2011 96 10 1548 1551 10.3324/haematol.2011.043786 21791474 103. Slamon DJ Godolphin W Jones LA Holt JA Wong SG Keith DE Levin WJ Stuart SG Udove J Ullrich A Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science (N Y) 1989 244 4905 707 712 10.1126/science.2470152 104. Zhang C Burger MC Jennewein L Genssler S Schonfeld K Zeiner P Hattingen E Harter PN Mittelbronn M Tonn T ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma J Natl Cancer Inst 2016 10.1093/jnci/djv375 27795228 105. Alsamah W Romia Y Modification of natural killer cells to target tumors Int J Pharm Clin Res 2014 6 1 97 100 106. Uherek C Tonn T Uherek B Becker S Schnierle B Klingemann HG Wels W Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction Blood 2002 100 4 1265 1273 10.1182/blood.V100.4.1265.h81602001265_1265_1273 12149207 107. Schonfeld K Sahm C Zhang C Naundorf S Brendel C Odendahl M Nowakowska P Bonig H Kohl U Kloess S Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor Mol Ther 2015 23 2 330 338 10.1038/mt.2014.219 25373520 108. Kruschinski A Moosmann A Poschke I Norell H Chmielewski M Seliger B Kiessling R Blankenstein T Abken H Charo J Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas Proc Natl Acad Sci USA 2008 105 45 17481 17486 10.1073/pnas.0804788105 18987320 109. Esser R Muller T Stefes D Kloess S Seidel D Gillies SD Aperlo-Iffland C Huston JS Uherek C Schonfeld K NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin J Cell Mol Med 2012 16 3 569 581 10.1111/j.1582-4934.2011.01343.x 21595822 110. Seidel D Shibina A Siebert N Wels WS Reynolds CP Huebener N Lode HN Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma Cancer Immunol Immunother CII 2015 64 5 621 634 10.1007/s00262-015-1669-5 25711293 111. Zhang G Liu R Zhu X Wang L Ma J Han H Wang X Zhang G He W Wang W Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody Immunol Cell Biol 2013 91 10 615 624 10.1038/icb.2013.45 24100387 112. Han J Chu J Keung Chan W Zhang J Wang Y Cohen JB Victor A Meisen WH Kim SH Grandi P CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells Sci Rep 2015 5 11483 10.1038/srep11483 26155832 113. Altvater B Landmeier S Pscherer S Temme J Schweer K Kailayangiri S Campana D Juergens H Pule M Rossig C 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells Clin Cancer Res 2009 15 15 4857 4866 10.1158/1078-0432.CCR-08-2810 19638467 114. Sahm C Schonfeld K Wels WS Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor Cancer Immunol Immunother CII 2012 61 9 1451 1461 10.1007/s00262-012-1212-x 22310931 115. Parsons DW Jones S Zhang X Lin JC Leary RJ Angenendt P Mankoo P Carter H Siu IM Gallia GL An integrated genomic analysis of human glioblastoma multiforme Science (N Y) 2008 321 5897 1807 1812 10.1126/science.1164382 116. Chen X Han J Chu J Zhang L Zhang J Chen C Chen L Wang Y Wang H Yi L A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases Oncotarget 2016 7 19 27764 27777 10.18632/oncotarget.8526 27050072 117. Cao B Liu M Wang L Liang B Feng Y Chen X Shi Y Zhang J Ye X Tian Y Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer Biochem Biophys Res Commun 2020 524 1 96 102 10.1016/j.bbrc.2020.01.053 31980173 118. Montagner IM Penna A Fracasso G Carpanese D Dalla Pieta A Barbieri V Zuccolotto G Rosato A Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer Cells 2020 9 6 1382 10.3390/cells9061382 7349573 119. Bollino D Webb TJ Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy Transl Res 2017 187 32 43 10.1016/j.trsl.2017.06.003 28651074 120. Xia N Haopeng P Gong JU Lu J Chen Z Zheng Y Wang Z Sun YU Yang Z Hoffman RM Robo1-specific CAR-NK immunotherapy enhances efficacy of (125)I seed brachytherapy in an orthotopic mouse model of human pancreatic carcinoma Anticancer Res 2019 39 11 5919 5925 10.21873/anticanres.13796 31704816 121. Savan R Chan T Young HA Lentiviral gene transduction in human and mouse NK cell lines Methods Mol Biol (Clifton, NJ) 2010 612 209 221 10.1007/978-1-60761-362-6_14 122. Danthinne X Imperiale MJ Production of first generation adenovirus vectors: a review Gene Ther 2000 7 20 1707 1714 10.1038/sj.gt.3301301 11083491 123. Hacein-Bey-Abina S Garrigue A Wang GP Soulier J Lim A Morillon E Clappier E Caccavelli L Delabesse E Beldjord K Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 J Clin Investig 2008 118 9 3132 3142 10.1172/JCI35700 18688285 124. Ranzani M Annunziato S Adams DJ Montini E Cancer gene discovery: exploiting insertional mutagenesis Mol Cancer Res MCR 2013 11 10 1141 1158 10.1158/1541-7786.MCR-13-0244 23928056 125. Felice B Cattoglio C Cittaro D Testa A Miccio A Ferrari G Luzi L Recchia A Mavilio F Transcription factor binding sites are genetic determinants of retroviral integration in the human genome PLoS ONE 2009 4 2 e4571 10.1371/journal.pone.0004571 19238208 126. Imamura M Shook D Kamiya T Shimasaki N Chai SM Coustan-Smith E Imai C Campana D Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15 Blood 2014 124 7 1081 1088 10.1182/blood-2014-02-556837 25006133 127. Cho FN Chang TH Shu CW Ko MC Liao SK Wu KH Yu MS Lin SJ Hong YC Chen CH Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis PLoS ONE 2014 9 10 e109352 10.1371/journal.pone.0109352 25313995 128. Nanbakhsh A Best B Riese M Rao S Wang L Medin J Thakar MS Malarkannan S Dextran enhances the lentiviral transduction efficiency of murine and human primary NK cells J Vis Exp JoVE 2018 10.3791/55063 29364266 129. Castellani S Orlando C Carbone A Di Gioia S Conese M Magnetofection enhances lentiviral-mediated transduction of airway epithelial cells through extracellular and cellular barriers Genes 2016 7 11 103 10.3390/genes7110103 5126789 130. Chang L Gallego-Perez D Zhao X Bertani P Yang Z Chiang CL Malkoc V Shi J Sen CK Odonnell L Dielectrophoresis-assisted 3D nanoelectroporation for non-viral cell transfection in adoptive immunotherapy Lab Chip 2015 15 15 3147 3153 10.1039/C5LC00553A 26105628 131. Becker PS Suck G Nowakowska P Ullrich E Seifried E Bader P Tonn T Seidl C Selection and expansion of natural killer cells for NK cell-based immunotherapy Cancer Immunol Immunother CII 2016 65 4 477 484 10.1007/s00262-016-1792-y 26810567 132. Fujisaki H Kakuda H Shimasaki N Imai C Ma J Lockey T Eldridge P Leung WH Campana D Expansion of highly cytotoxic human natural killer cells for cancer cell therapy Can Res 2009 69 9 4010 4017 10.1158/0008-5472.CAN-08-3712 133. Lim SA Kim TJ Lee JE Sonn CH Kim K Kim J Choi JG Choi IK Yun CO Kim JH Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy Can Res 2013 73 8 2598 2607 10.1158/0008-5472.CAN-12-2893 134. Sutlu T Stellan B Gilljam M Quezada HC Nahi H Gahrton G Alici E Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor Cytotherapy 2010 12 8 1044 1055 10.3109/14653249.2010.504770 20795758 135. Denman CJ Senyukov VV Somanchi SS Phatarpekar PV Kopp LM Johnson JL Singh H Hurton L Maiti SN Huls MH Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells PLoS ONE 2012 7 1 e30264 10.1371/journal.pone.0030264 22279576 136. Shah N Martin-Antonio B Yang H Ku S Lee DA Cooper LJ Decker WK Li S Robinson SN Sekine T Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity PLoS ONE 2013 8 10 e76781 10.1371/journal.pone.0076781 24204673 137. Kloss S Oberschmidt O Morgan M Dahlke J Arseniev L Huppert V Granzin M Gardlowski T Matthies N Soltenborn S Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells Hum Gene Ther 2017 28 10 897 913 10.1089/hum.2017.157 28810809 138. Martin-Antonio B Sune G Perez-Amill L Castella M Urbano-Ispizua A Natural killer cells: angels and devils for immunotherapy Int J Mol Sci 2017 18 9 1868 10.3390/ijms18091868 139. Pinthus JH Waks T Kaufman-Francis K Schindler DG Harmelin A Kanety H Ramon J Eshhar Z Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes Can Res 2003 63 10 2470 2476 140. Topfer K Cartellieri M Michen S Wiedemuth R Muller N Lindemann D Bachmann M Fussel M Schackert G Temme A DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy J Immunol 2015 194 7 3201 3212 10.4049/jimmunol.1400330 25740942 141. Meier R Golovko D Tavri S Henning TD Knopp C Piontek G Rudelius M Heinrich P Wels WS Daldrup-Link H Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging Magn Reson Med 2011 65 3 756 763 10.1002/mrm.22652 20928869 142. Liu Y Zhou Y Huang KH Fang X Li Y Wang F An L Chen Q Zhang Y Shi A Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor Cell Prolif 2020 53 8 e12858 10.1111/cpr.12858 32592435 143. Hu Z Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer Sci Rep 2020 10 1 2815 10.1038/s41598-020-59736-3 32071339 144. Wei J Han X Bo J Han W Target selection for CAR-T therapy J Hematol Oncol 2019 12 1 62 10.1186/s13045-019-0758-x 31221182 145. Guo Y Wang Y Han W Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects J Immunol Res 2016 2016 3850839 26998495 146. Adusumilli PS Cherkassky L Villena-Vargas J Colovos C Servais E Plotkin J Jones DR Sadelain M Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity Sci Transl Med 2014 6 261 261151 10.1126/scitranslmed.3010162 147. Santoro SP Kim S Motz GT Alatzoglou D Li C Irving M Powell DJ Jr Coukos G T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression Cancer Immunol Res 2015 3 1 68 84 10.1158/2326-6066.CIR-14-0192 25358763 148. Gordon IO Tretiakova MS Noffsinger AE Hart J Reuter VE Al-Ahmadie HA Prostate-specific membrane antigen expression in regeneration and repair Mod Pathol 2008 21 12 1421 1427 10.1038/modpathol.2008.143 18839017 149. Alkins R Burgess A Kerbel R Wels WS Hynynen K Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival Neuro-oncology 2016 18 7 974 981 10.1093/neuonc/nov318 26819443 150. Carrega P Morandi B Costa R Frumento G Forte G Altavilla G Ratto GB Mingari MC Moretta L Ferlazzo G Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells Cancer 2008 112 4 863 875 10.1002/cncr.23239 18203207 151. Wennerberg E Kremer V Childs R Lundqvist A CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo Cancer Immunol Immunother CII 2015 64 2 225 235 10.1007/s00262-014-1629-5 25344904 152. Kremer V Ligtenberg MA Zendehdel R Seitz C Duivenvoorden A Wennerberg E Colón E Scherman-Plogell AH Lundqvist A Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma J Immunother Cancer 2017 5 1 73 10.1186/s40425-017-0275-9 28923105 153. Muller N Michen S Tietze S Topfer K Schulte A Lamszus K Schmitz M Schackert G Pastan I Temme A Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1alpha-secreting glioblastoma J Immunother 2015 38 5 197 210 10.1097/CJI.0000000000000082 25962108 154. Hou W Chen H Rojas J Sampath P Thorne SH Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF Int J Cancer 2014 135 5 1238 1246 10.1002/ijc.28747 24474587 155. Sampath P Li J Hou W Chen H Bartlett DL Thorne SH Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects Mol Ther 2013 21 3 620 628 10.1038/mt.2012.257 23229093 156. Heyman B Yang Y Chimeric antigen receptor T cell therapy for solid tumors: current status, obstacles and future strategies Cancers 2019 11 2 191 10.3390/cancers11020191 157. Otegbeye F Ojo E Moreton S Mackowski N Lee DA de Lima M Wald DN Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models PLoS ONE 2018 13 1 e0191358 10.1371/journal.pone.0191358 29342200 158. Zhang C Hu Y Shi C Targeting natural killer cells for tumor immunotherapy Front Immunol 2020 11 60 10.3389/fimmu.2020.00060 32140153 159. Wang QM Tang PM Lian GY Li C Li J Huang XR Lan HY Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells Cancer Immunol Res. 2018 6 8 965 977 10.1158/2326-6066.CIR-17-0491 29915022 160. Zhu S Denman CJ Cobanoglu ZS Kiany S Lau CC Gottschalk SM Hughes DP Kleinerman ES Lee DA The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells Pharm Res 2015 32 3 779 792 10.1007/s11095-013-1231-0 24203492 161. Balsamo M Manzini C Pietra G Raggi F Blengio F Mingari MC Varesio L Moretta L Bosco MC Vitale M Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC Eur J Immunol 2013 43 10 2756 2764 10.1002/eji.201343448 23913266 162. Wang J Lupo KB Chambers AM Matosevic S Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells J Immunother Cancer 2018 6 1 136 10.1186/s40425-018-0441-8 30514403 163. Chan CJ Martinet L Gilfillan S Souza-Fonseca-Guimaraes F Chow MT Town L Ritchie DS Colonna M Andrews DM Smyth MJ The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions Nat Immunol 2014 15 5 431 438 10.1038/ni.2850 24658051 164. Dong W Wu X Ma S Wang Y Nalin AP Zhu Z Zhang J Benson DM He K Caligiuri MA The mechanism of anti-PD-L1 Antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector Cancer Discov 2019 9 10 1422 1437 10.1158/2159-8290.CD-18-1259 31340937 165. Grosser R Cherkassky L Chintala N Adusumilli PS Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors Cancer Cell 2019 36 5 471 482 10.1016/j.ccell.2019.09.006 31715131 166. Fabian KP Padget MR Donahue RN Solocinski K Robbins Y Allen CT Lee JH Rabizadeh S Soon-Shiong P Schlom J PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations J Immunother Cancer 2020 10.1136/jitc-2019-000450 32439799 167. Walseng E Koksal H Sektioglu IM Fane A Skorstad G Kvalheim G Gaudernack G Inderberg EM Walchli S A TCR-based chimeric antigen receptor Sci Rep 2017 7 1 10713 10.1038/s41598-017-11126-y 28878363 168. Ligtenberg MA Mougiakakos D Mukhopadhyay M Witt K Lladser A Chmielewski M Riet T Abken H Kiessling R Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity J Immunol 2016 196 2 759 766 10.4049/jimmunol.1401710 26673145 169. Carlsten M Childs RW Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications Front Immunol 2015 6 266 10.3389/fimmu.2015.00266 26113846 170. Mohammed S Sukumaran S Bajgain P Watanabe N Heslop HE Rooney CM Brenner MK Fisher WE Leen AM Vera JF Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer Mol Ther 2017 25 1 249 258 10.1016/j.ymthe.2016.10.016 28129119 171. Wang Z Guo L Song Y Zhang Y Lin D Hu B Mei Y Sandikin D Liu H Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-betaR II and NKG2D Cancer Immunol Immunother CII 2017 66 4 537 548 10.1007/s00262-017-1959-1 28184969 172. Fan M Li M Gao L Geng S Wang J Wang Y Yan Z Yu L Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia J Hematol Oncol 2017 10 1 151 10.1186/s13045-017-0519-7 28851445 173. Lu C Guo C Chen H Zhang H Zhi L Lv T Li M Niu Z Lu P Zhu W A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis Mol Immunol 2020 122 200 206 10.1016/j.molimm.2020.04.016 32388482 174. Schambach A Morgan M Retroviral vectors for cancer gene therapy. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2016 209 17 35 28101685 175. Dufva O Koski J Maliniemi P Ianevski A Klievink J Leitner J Pölönen P Hohtari H Saeed K Hannunen T Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity Blood 2020 135 9 597 609 10.1182/blood.2019002121 31830245 176. Ureña-Bailén G Lamsfus-Calle A Daniel-Moreno A Raju J Schlegel P Seitz C Atar D Antony JS Handgretinger R Mezger M CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies Brief Funct Genom 2020 19 3 191 200 10.1093/bfgp/elz039 177. Michieletto D Lusic M Marenduzzo D Orlandini E Physical principles of retroviral integration in the human genome Nat Commun 2019 10 1 575 10.1038/s41467-019-08333-8 30718508 178. Ren J Zhao Y Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9 Protein Cell 2017 8 9 634 643 10.1007/s13238-017-0410-x 28434148 179. Ren J Liu X Fang C Jiang S June CH Zhao Y Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition Clin Cancer Res 2017 23 9 2255 2266 10.1158/1078-0432.CCR-16-1300 27815355 180. Afolabi LO Adeshakin AO Sani MM Bi J Wan X Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9 Immunology 2019 158 2 63 69 10.1111/imm.13094 31315144 181. Naeimi Kararoudi M Dolatshad H Trikha P Hussain SA Elmas E Foltz JA Moseman JE Thakkar A Nakkula RJ Lamb M Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins J Vis Exp JoVE 2018 10.3791/58237 29985369 182. Rautela J, Surgenor E, Huntington ND. Efficient genome editing of human natural killer cells by CRISPR RNP. bioRxiv 2018:406934. 183. Liu X Zhang Y Cheng C Cheng AW Zhang X Li N Xia C Wei X Liu X Wang H CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells Cell Res 2017 27 1 154 157 10.1038/cr.2016.142 27910851 184. Nakazawa T Natsume A Nishimura F Morimoto T Matsuda R Nakamura M Yamada S Nakagawa I Motoyama Y Park YS Effect of CRISPR/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth Cells 2020 9 4 998 10.3390/cells9040998 7227242 185. Tang N Cheng C Zhang X Qiao M Li N Mu W Wei XF Han W Wang H TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors JCI Insight 2020 5 4 e133977 10.1172/jci.insight.133977 7101140 186. Michen S Temme A Genetically engineered natural killer cells as a means for adoptive tumor immunotherapy Crit Rev Immunol 2016 36 4 329 347 10.1615/CritRevImmunol.2017019376 28322137 187. Chu Y Yahr A Huang B Ayello J Barth M M SC: Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice Oncoimmunology 2017 6 9 e1341031 10.1080/2162402X.2017.1341031 28932644 188. Siegler EL Kim YJ Chen X Siriwon N Mac J Rohrs JA Bryson PD Wang P Combination cancer therapy using chimeric antigen receptor-engineered natural killer cells as drug carriers Mol Ther 2017 25 12 2607 2619 10.1016/j.ymthe.2017.08.010 28919377 189. Zhang Q Tian K Xu J Zhang H Li L Fu Q Chai D Li H Zheng J Synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma J Immunol Res 2017 2017 6915912 29423418 190. Felices M Lenvik TR Davis ZB Miller JS Vallera DA Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells Methods Mol Biol 2016 1441 333 346 10.1007/978-1-4939-3684-7_28 27177679 191. Klingemann H Boissel L Targeted cellular therapy with natural killer cells Hormone and Metab Res 2008 40 2 122 125 10.1055/s-2007-1004576 192. Battella S Cox MC Santoni A Palmieri G Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions J Leukoc Biol 2016 99 1 87 96 10.1189/jlb.5VMR0415-141R 26136506 193. Zhen A Kamata M Rezek V Rick J Levin B Kasparian S Chen IS Yang OO Zack JA Kitchen SG HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells Mol Ther 2015 23 8 1358 1367 10.1038/mt.2015.102 26050990 194. Gschweng E De Oliveira S Kohn DB Hematopoietic stem cells for cancer immunotherapy Immunol Rev 2014 257 1 237 249 10.1111/imr.12128 24329801 195. Lowe E Truscott LC De Oliveira SN In vitro generation of Human NK cells expressing chimeric antigen receptor through differentiation of gene-modified hematopoietic stem cells Methods Mol Biol (Clifton, NJ) 2016 1441 241 251 10.1007/978-1-4939-3684-7_20 196. Tammana S Huang X Wong M Milone MC Ma L Levine BL June CH Wagner JE Blazar BR Zhou X 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies Hum Gene Ther 2010 21 1 75 86 10.1089/hum.2009.122 19719389 197. Chang YH Connolly J Shimasaki N Mimura K Kono K Campana D A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells Can Res 2013 73 6 1777 1786 10.1158/0008-5472.CAN-12-3558 198. Lanier LL Corliss B Wu J Phillips JH Association of DAP12 with activating CD94/NKG2C NK cell receptors Immunity 1998 8 6 693 701 10.1016/S1074-7613(00)80574-9 9655483 199. Carr WH Rosen DB Arase H Nixon DF Michaelsson J Lanier LL Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, Encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation J Immunol 2007 178 2 647 651 10.4049/jimmunol.178.2.647 17202323 200. Orange JS Harris KE Andzelm MM Valter MM Geha RS Strominger JL The mature activating natural killer cell immunologic synapse is formed in distinct stages Proc Natl Acad Sci USA 2003 100 24 14151 14156 10.1073/pnas.1835830100 14612578 201. Mukherjee M Mace EM Carisey AF Ahmed N Orange JS Quantitative imaging approaches to study the CAR immunological synapse Mol Ther 2017 25 8 1757 1768 10.1016/j.ymthe.2017.06.003 28663103 202. Xiong W Chen Y Kang X Chen Z Zheng P Hsu YH Jang JH Qin L Liu H Dotti G Immunological synapse predicts effectiveness of chimeric antigen receptor cells Mol Ther 2018 26 4 963 975 10.1016/j.ymthe.2018.01.020 29503199 203. Srivastava S Riddell SR Engineering CAR-T cells: design concepts Trends Immunol 2015 36 8 494 502 10.1016/j.it.2015.06.004 26169254 204. Shevtsov M Multhoff G Immunological and translational aspects of NK cell-based antitumor immunotherapies Front Immunol 2016 7 492 27891129 205. Pockley AG Vaupel P Multhoff G NK cell-based therapeutics for lung cancer Expert Opin Biol Ther 2020 20 1 23 33 10.1080/14712598.2020.1688298 31714156 206. Lasek W Zagożdżon R Jakobisiak M Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother CII 2014 63 5 419 435 10.1007/s00262-014-1523-1 24514955 207. Buller CW Mathew PA Mathew SO Roles of NK cell receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in cancer Cancers 2020 12 7 1755 10.3390/cancers12071755 208. Armeanu S Bitzer M Lauer UM Venturelli S Pathil A Krusch M Kaiser S Jobst J Smirnow I Wagner A Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate Can Res 2005 65 14 6321 6329 10.1158/0008-5472.CAN-04-4252 209. Parihar R Rivas C Huynh M Omer B Lapteva N Metelitsa LS Gottschalk SM Rooney CM NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors Cancer Immunol Res 2019 7 3 363 375 10.1158/2326-6066.CIR-18-0572 30651290 210. Vey N Karlin L Sadot-Lebouvier S Broussais F Berton-Rigaud D Rey J Charbonnier A Marie D André P Paturel C A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies Oncotarget 2018 9 25 17675 17688 10.18632/oncotarget.24832 29707140 211. Terszowski G Klein C Schmied L Stern M How to outsmart NK cell tolerance Oncoimmunology 2015 4 9 e1016708 10.1080/2162402X.2015.1016708 26405590 212. Aranda F Vacchelli E Eggermont A Galon J Fridman WH Zitvogel L Kroemer G Galluzzi L Trial watch: immunostimulatory monoclonal antibodies in cancer therapy Oncoimmunology 2014 3 1 e27297 10.4161/onci.27297 24701370 213. Faden DL Concha-Benavente F Chakka AB McMichael EL Chandran U Ferris RL Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma Head Neck 2019 41 8 2591 2601 10.1002/hed.25726 30828910 214. Kohrt HE Thielens A Marabelle A Sagiv-Barfi I Sola C Chanuc F Fuseri N Bonnafous C Czerwinski D Rajapaksa A Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies Blood 2014 123 5 678 686 10.1182/blood-2013-08-519199 24326534 215. Yalniz FF Daver N Rezvani K Kornblau S Ohanian M Borthakur G DiNardo CD Konopleva M Burger J Gasior Y A pilot trial of lirilumab with or without azacitidine for patients with myelodysplastic syndrome Clin Lymphoma Myeloma Leukemia 2018 18 10 658 663.e652 10.1016/j.clml.2018.06.011 216. Carlsten M Korde N Kotecha R Reger R Bor S Kazandjian D Landgren O Childs RW Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma Clin Cancer Res 2016 22 21 5211 5222 10.1158/1078-0432.CCR-16-1108 27307594 217. Benson DM Jr Cohen AD Jagannath S Munshi NC Spitzer G Hofmeister CC Efebera YA Andre P Zerbib R Caligiuri MA A phase I trial of the anti-kir antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma Clin Cancer Res 2015 21 18 4055 4061 10.1158/1078-0432.CCR-15-0304 25999435 218. Korde N Carlsten M Lee MJ Minter A Tan E Kwok M Manasanch E Bhutani M Tageja N Roschewski M A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma Haematologica 2014 99 6 e81 83 10.3324/haematol.2013.103085 24658821 219. Häusler SF Del Barrio IM Diessner J Stein RG Strohschein J Hönig A Dietl J Wischhusen J Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion Am J Transl Res 2014 6 2 129 139 24489992 220. Bhat R Watzl C Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies PLoS ONE 2007 2 3 e326 10.1371/journal.pone.0000326 17389917 221. Lin JK Muffly LS Spinner MA Barnes JI Owens DK Goldhaber-Fiebert JD Cost effectiveness of chimeric antigen receptor t-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma J Clin Oncol 2019 37 24 2105 2119 10.1200/JCO.18.02079 31157579 222. Su S Betters DM Ramanathan M Keyvanfar K Smith A Feng X Furutani E Carlsten M Lundqvist A Childs R Optimizing lentiviral transduction of human natural killer cells Blood 2011 118 4714 10.1182/blood.V118.21.4714.4714 21765019 223. Micucci F Zingoni A Piccoli M Frati L Santoni A Galandrini R High-efficient lentiviral vector-mediated gene transfer into primary human NK cells Exp Hematol 2006 34 10 1344 1352 10.1016/j.exphem.2006.06.001 16982327 224. Sutlu T Nystrom S Gilljam M Stellan B Applequist SE Alici E Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy Hum Gene Ther 2012 23 10 1090 1100 10.1089/hum.2012.080 22779406 225. Tran J Kung SK Lentiviral vectors mediate stable and efficient gene delivery into primary murine natural killer cells Mol Ther 2007 15 7 1331 1339 10.1038/sj.mt.6300184 17505478 226. Boissel L Betancur M Lu W Wels WS Marino T Van Etten RA Klingemann H Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens Leukemia Lymphoma 2012 53 5 958 965 10.3109/10428194.2011.634048 22023526 227. Guven H Konstantinidis KV Alici E Aints A Abedi-Valugerdi M Christensson B Ljunggren HG Dilber MS Efficient gene transfer into primary human natural killer cells by retroviral transduction Exp Hematol 2005 33 11 1320 1328 10.1016/j.exphem.2005.07.006 16263416 228. Dai H Wu Z Jia H Tong C Guo Y Ti D Han X Liu Y Zhang W Wang C Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia J Hematol Oncol 2020 13 1 30 10.1186/s13045-020-00856-8 32245502 229. Guillerey C Huntington ND Smyth MJ Targeting natural killer cells in cancer immunotherapy Nat Immunol 2016 17 9 1025 1036 10.1038/ni.3518 27540992 230. Rossi GR Trindade ES Souza-Fonseca-Guimaraes F Tumor microenvironment-associated extracellular matrix components regulate NK cell function Front Immunol 2020 11 73 10.3389/fimmu.2020.00073 32063906